StemCell Therapy

First Overall Survival Analysis for KEYTRUDA Plus LENVIMA Combination in a Phase 3 Study in Advanced Endometrial Cancer

KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 Study

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the pivotal Phase 3 KEYNOTE-775/Study 309 trial evaluating the investigational use of KEYTRUDA, Mercks anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) and its secondary efficacy endpoint of objective response rate (ORR) in patients with advanced endometrial cancer following at least one prior platinum-based regimen. These positive results were observed in the mismatch repair proficient (pMMR) subgroup and the intention-to-treat (ITT) study population, which includes both patients with endometrial carcinoma that is pMMR as well as patients whose disease is microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR). Based on an analysis conducted by an independent Data Monitoring Committee, KEYTRUDA plus LENVIMA demonstrated a statistically significant and clinically meaningful improvement in OS, PFS and ORR versus chemotherapy (treatment of physicians choice [TPC] of doxorubicin or paclitaxel). The safety profile of the KEYTRUDA plus LENVIMA combination was consistent with previously reported studies. Merck and Eisai will discuss these data with regulatory authorities worldwide, with the intent to submit marketing authorization applications based on these results, and plan to present these results at an upcoming medical meeting.

Women with advanced endometrial cancer are faced with high mortality rates and limited treatment options following initial systemic therapy, said Dr. Gregory Lubiniecki, Associate Vice President, Oncology Clinical Research, Merck Research Laboratories. These are the first results from a Phase 3 trial of a combination regimen including immunotherapy in advanced endometrial carcinoma that have shown a statistically significant improvement in overall survival, progression-free survival and objective response rate versus chemotherapy. Merck and Eisai are dedicated to continuing to research the KEYTRUDA plus LENVIMA combination and discover new approaches to address unmet needs for devastating diseases such as endometrial carcinoma.

We are encouraged by the data observed in KEYNOTE-775/Study 309, which represent a possible step forward for patients impacted by advanced endometrial carcinoma and support the results seen in the advanced endometrial cancer cohort of KEYNOTE-146/Study 111, said Dr. Takashi Owa, Vice President, Chief Medicine Creation Officer and Chief Discovery Officer, Oncology Business Group at Eisai. As more clinical data from the LEAP (LEnvatinib And Pembrolizumab) program are revealed, we cannot help but be energized by the trajectory of our collaboration with Merck and the benefits we hope to provide to patients together. Most importantly, we are grateful for the trust that the patients and healthcare professionals who participated in this trial have shown us.

KEYNOTE-775/Study 309 is the confirmatory trial for KEYNOTE-146/Study 111, which supported the U.S. Food and Drug Administrations (FDA) 2019 accelerated approval of the KEYTRUDA plus LENVIMA combination for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation. This accelerated approval was based on tumor response rate and durability of response and was the first approval granted under Project Orbis, an initiative of the FDA Oncology Center of Excellence that provides a framework for concurrent submission and review of oncology drugs among its international partners. Under Project Orbis, Health Canada and Australias Therapeutic Goods Administration (TGA) granted conditional and provisional approvals, respectively, for this indication.

Merck and Eisai are studying the KEYTRUDA plus LENVIMA combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program in 13 different tumor types across 20 clinical trials, including a Phase 3 trial evaluating the combination in the first-line setting for patients with advanced endometrial carcinoma (LEAP-001).

About KEYNOTE-775/Study 309

KEYNOTE-775/Study 309 is a multicenter, randomized, open-label, Phase 3 trial ( ClinicalTrials.gov , NCT03517449 ) evaluating KEYTRUDA in combination with LENVIMA in patients with advanced endometrial cancer following at least one prior platinum-based regimen. The dual primary endpoints are OS and PFS, as assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors Version (RECIST) v1.1. Select secondary endpoints include objective response rate (ORR) by BICR per RECIST v1.1 and safety/tolerability. Of the 827 patients enrolled, 697 patients had tumors that were non-MSI-H or pMMR, and 130 patients had tumors that were MSI-H or dMMR. Patients were randomized 1:1 to receive:

About Endometrial Cancer

Endometrial cancer begins in the inner lining of the uterus, which is known as the endometrium and is the most common type of cancer in the uterus. In 2018, it was estimated there were more than 382,000 new cases and nearly 90,000 deaths from uterine body cancers worldwide (these estimates include both endometrial cancers and uterine sarcomas; more than 90% of uterine body cancers occur in the endometrium, so the actual numbers for endometrial cancer cases and deaths are slightly lower than these estimates). In the U.S., it is estimated there will be almost 66,000 new cases of uterine body cancer and nearly 13,000 deaths from the disease in 2020. The five-year survival rate for advanced or metastatic endometrial cancer (stage IV) is estimated to be approximately 17%.

About KEYTRUDA (pembrolizumab) Injection, 100 mg

KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the bodys immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

Merck has the industrys largest immuno-oncology clinical research program. There are currently more than 1,300 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patients likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.

Selected KEYTRUDA (pembrolizumab) Indications in the U.S.

Melanoma

KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.

KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

Non-Small Cell Lung Cancer

KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) 1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.

KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS 1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.

Small Cell Lung Cancer

KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least 1 other prior line of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Head and Neck Squamous Cell Cancer

KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [combined positive score (CPS) 1] as determined by an FDA-approved test.

KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

Classical Hodgkin Lymphoma

KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL).

KEYTRUDA is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.

Primary Mediastinal Large B-Cell Lymphoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.

Urothelial Carcinoma

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 (CPS 10), as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

KEYTRUDA is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Microsatellite Instability-High or Mismatch Repair Deficient Cancer

KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.

Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer

KEYTRUDA is indicated for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).

Gastric Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Esophageal Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS 10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.

Cervical Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Hepatocellular Carcinoma

KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Merkel Cell Carcinoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Renal Cell Carcinoma

KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

Endometrial Carcinoma

KEYTRUDA, in combination with LENVIMA, is indicated for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.

Tumor Mutational Burden-High

KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [10 mutations/megabase] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.

Cutaneous Squamous Cell Carcinoma

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

Triple-Negative Breast Cancer

KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS 10) as determined by an FDA-approved test. This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Selected Important Safety Information for KEYTRUDA

Severe and Fatal Immune-Mediated Adverse Reactions

KEYTRUDA is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or the programmed death ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, can affect more than one body system simultaneously, and can occur at any time after starting treatment or after discontinuation of treatment.

Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Early identification and management are essential to ensure safe use of antiPD-1/PD-L1 treatments. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue KEYTRUDA depending on severity of the immune-mediated adverse reaction. In general, if KEYTRUDA requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose adverse reactions are not controlled with corticosteroid therapy.

Immune-Mediated Pneumonitis

KEYTRUDA can cause immune-mediated pneumonitis. The incidence is higher in patients who have received prior thoracic radiation. Immune-mediated pneumonitis occurred in 3.4% (94/2799) of patients receiving KEYTRUDA, including fatal (0.1%), Grade 4 (0.3%), Grade 3 (0.9%), and Grade 2 (1.3%) reactions. Systemic corticosteroids were required in 67% (63/94) of patients. Pneumonitis led to permanent discontinuation of KEYTRUDA in 1.3% (36) and withholding in 0.9% (26) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 23% had recurrence. Pneumonitis resolved in 59% of the 94 patients.

Pneumonitis occurred in 8% (31/389) of adult patients with cHL receiving KEYTRUDA as a single agent, including Grades 3-4 in 2.3% of patients. Patients received high-dose corticosteroids for a median duration of 10 days (range: 2 days to 53 months). Pneumonitis rates were similar in patients with and without prior thoracic radiation. Pneumonitis led to discontinuation of KEYTRUDA in 5.4% (21) of patients, 42% of these patients interrupted KEYTRUDA, 68% discontinued KEYTRUDA, and 77% had resolution.

Immune-Mediated Colitis

KEYTRUDA can cause immune-mediated colitis, which may present with diarrhea. Cytomegalovirus infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. Immune-mediated colitis occurred in 1.7% (48/2799) of patients receiving KEYTRUDA, including Grade 4 (

Hepatotoxicity and Immune-Mediated Hepatitis

KEYTRUDA as a Single Agent

KEYTRUDA can cause immune-mediated hepatitis. Immune-mediated hepatitis occurred in 0.7% (19/2799) of patients receiving KEYTRUDA, including Grade 4 (

KEYTRUDA with Axitinib

KEYTRUDA in combination with axitinib can cause hepatic toxicity. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider monitoring more frequently as compared to when the drugs are administered as single agents. For elevated liver enzymes, interrupt KEYTRUDA and axitinib, and consider administering corticosteroids as needed. With the combination of KEYTRUDA and axitinib, Grades 3 and 4 increased alanine aminotransferase (ALT) (20%) and increased aspartate aminotransferase (AST) (13%) were seen, which was at a higher frequency compared to KEYTRUDA alone. Fifty-nine percent of the patients with increased ALT received systemic corticosteroids. In patients with ALT 3 times upper limit of normal (ULN) (Grades 2-4, n=116), ALT resolved to Grades 0-1 in 94%. Among the 92 patients who were rechallenged with either KEYTRUDA (n=3) or axitinib (n=34) administered as a single agent or with both (n=55), recurrence of ALT 3 times ULN was observed in 1 patient receiving KEYTRUDA, 16 patients receiving axitinib, and 24 patients receiving both. All patients with a recurrence of ALT 3 ULN subsequently recovered from the event.

Immune-Mediated Endocrinopathies

Adrenal Insufficiency

KEYTRUDA can cause primary or secondary adrenal insufficiency. For Grade 2 or higher, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold KEYTRUDA depending on severity. Adrenal insufficiency occurred in 0.8% (22/2799) of patients receiving KEYTRUDA, including Grade 4 (

Hypophysitis

KEYTRUDA can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Hypophysitis occurred in 0.6% (17/2799) of patients receiving KEYTRUDA, including Grade 4 (

Thyroid Disorders

KEYTRUDA can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue KEYTRUDA depending on severity. Thyroiditis occurred in 0.6% (16/2799) of patients receiving KEYTRUDA, including Grade 2 (0.3%). None discontinued, but KEYTRUDA was withheld in

Hyperthyroidism occurred in 3.4% (96/2799) of patients receiving KEYTRUDA, including Grade 3 (0.1%) and Grade 2 (0.8%). It led to permanent discontinuation of KEYTRUDA in

Type 1 Diabetes Mellitus (DM), Which Can Present With Diabetic Ketoacidosis

Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold KEYTRUDA depending on severity. Type 1 DM occurred in 0.2% (6/2799) of patients receiving KEYTRUDA. It led to permanent discontinuation in

Immune-Mediated Nephritis With Renal Dysfunction

KEYTRUDA can cause immune-mediated nephritis. Immune-mediated nephritis occurred in 0.3% (9/2799) of patients receiving KEYTRUDA, including Grade 4 (

Immune-Mediated Dermatologic Adverse Reactions

KEYTRUDA can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson syndrome, drug rash with eosinophilia and systemic symptoms, and toxic epidermal necrolysis, has occurred with antiPD-1/PD-L1 treatments. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate nonexfoliative rashes. Withhold or permanently discontinue KEYTRUDA depending on severity. Immune-mediated dermatologic adverse reactions occurred in 1.4% (38/2799) of patients receiving KEYTRUDA, including Grade 3 (1%) and Grade 2 (0.1%) reactions. Systemic corticosteroids were required in 40% (15/38) of patients. These reactions led to permanent discontinuation in 0.1% (2) and withholding of KEYTRUDA in 0.6% (16) of patients. All patients who were withheld reinitiated KEYTRUDA after symptom improvement; of these, 6% had recurrence. The reactions resolved in 79% of the 38 patients.

Other Immune-Mediated Adverse Reactions

The following clinically significant immune-mediated adverse reactions occurred at an incidence of Cardiac/Vascular: Myocarditis, pericarditis, vasculitis; Nervous System: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barr syndrome, nerve paresis, autoimmune neuropathy; Ocular: Uveitis, iritis and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss; Gastrointestinal: Pancreatitis, to include increases in serum amylase and lipase levels, gastritis, duodenitis; Musculoskeletal and Connective Tissue: Myositis/polymyositis, rhabdomyolysis (and associated sequelae, including renal failure), arthritis (1.5%), polymyalgia rheumatica; Endocrine: Hypoparathyroidism; Hematologic/Immune: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection.

Infusion-Related Reactions

KEYTRUDA can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in 0.2% of 2799 patients receiving KEYTRUDA. Monitor for signs and symptoms of infusion-related reactions. Interrupt or slow the rate of infusion for Grade 1 or Grade 2 reactions. For Grade 3 or Grade 4 reactions, stop infusion and permanently discontinue KEYTRUDA.

Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after antiPD-1/PD-L1 treatment. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute and chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between antiPD-1/PD-L1 treatment and allogeneic HSCT. Follow patients closely for evidence of these complications and intervene promptly. Consider the benefit vs risks of using antiPD-1/PD-L1 treatments prior to or after an allogeneic HSCT.

Increased Mortality in Patients With Multiple Myeloma

In trials in patients with multiple myeloma, the addition of KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of these patients with an antiPD-1/PD-L1 treatment in this combination is not recommended outside of controlled trials.

See the original post:
KEYTRUDA Plus LENVIMA Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective...

COVID-19 is currently the leading cause of death in the United States killing more people each day than heart disease or cancer.

To help stem the tide of this life-threatening disease, scientists around the world have been working to develop vaccines.

Last week, the Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the first of these vaccines, developed by Pfizer and BioNTech.

The EUA allows for the distribution of the Pfizer-BioNTech COVID-19 vaccine across the United States. This vaccine has been developed to prevent COVID-19 in people age 16 years and older.

Getting 2 doses of the vaccine may drastically reduce your chances of developing COVID-19.

Even if youve had COVID-19, getting the vaccine may help prevent reinfection and lower your risk of getting sick again.

Were really happy to have a safe and effective tool [against COVID-19], Dr. Iahn Gonsenhauser, chief quality and patient safety officer at The Ohio State University Wexner Medical Center in Columbus, Ohio, told Healthline.

Were encouraging everybody to explore their opportunity to access the COVID vaccine as soon as thats made available to them, he said.

When someone develops COVID-19, their immune system learns to recognize the virus and begins to produce antibodies to fight against it.

If that person recovers from the disease, they may have immunity against reinfection with the virus for a period of time afterwards.

However, questions remain about how long that immunity lasts.

We dont know how long the immunity triggered by infection persists, and someone infected in the spring may no longer be immunologically protected now in December, Dr. David Hirschwerk, an infectious disease specialist at Northwell Health in Manhasset, New York, told Healthline.

It does stand to reason that somebody with COVID-19 infection is likely immune for 3 to 4 months at least, he said, but we dont have firm data to support this yet.

Cases of reinfection with the virus that causes COVID-19 have been reported.

Getting vaccinated may help to strengthen immunity against COVID-19.

In an ongoing clinical trial, Pfizer and BioNTech have studied their vaccine in people with and without a history of exposure to the virus.

Their research to date has found the vaccine is 95 percent effective at preventing COVID-19.

Their findings suggest it may help prevent reinfection in people who have already been exposed to the virus, as well as lowering the risk of infection in people with no history of exposure.

Data from the phase 2/3 trial for the Pfizer-BioNTech vaccine suggest that the vaccine is safe and likely effective in persons with previous evidence of SARS-CoV-2 infection, said Dr. Miriam Smith, chief of infectious disease at Long Island Jewish Forest Hills in Queens, New York.

[The] vaccine should be offered to all persons regardless of history of prior symptomatic or asymptomatic infection, she said.

The Centers for Disease Control and Prevention (CDC) currently advises that people with a known history of COVID-19 may wait up to nearly 90 days after their prior infection to get vaccinated, if they prefer to do so.

While more research is needed, available evidence suggests that reinfection with this virus is rare within 90 days of initial infection.

If someone currently has active symptoms of COVID-19, the CDC recommends they wait to get vaccinated until theyve recovered and met the criteria for ending isolation.

The Pfizer-BioNTech COVID-19 vaccine carries some risk of side effects.

However, ongoing research suggests the side effects tend to be mild and short-lived.

The way that we generally approach these questions in healthcare is through risk-benefit analysis, Gonsenhauser said.

In this case, the risk of some adverse response to the vaccine is low, and the benefit of knowing that you have a potentially extended or refreshed immunity to COVID is significant, he said.

With that, were recommending that people get the vaccine, even if theyve already had a COVID exposure and infection, he continued.

The most commonly reported side effect associated with the Pfizer-BioNTech COVID-19 vaccine is pain around the injection site.

Some people who received the vaccine developed other side effects such as fatigue, headache, and muscle aches, which tend to resolve within a day or so.

The risk of severe adverse events following the vaccine appears to be very low. However, some groups of people might face higher risk of adverse reactions than others.

For example, if you have a history of severe allergic reaction to any of the ingredients contained in the vaccine, the FDA recommends that you not receive it.

Talk with your doctor to learn more about the potential benefits and risks of getting vaccinated against COVID-19.

More here:
Even if You've Had COVID-19 You Still Need the Vaccine - Healthline

SynDevRx is working to address the unmet medical need in the field of metabo-oncology by developing treatments for cancer patients who are overweight or have systemic metabolic dysfunction. Technology Networks recently spoke with Jim Shanahan,co-founder, vice president of business development and director of SynDevRx, to explore the impact of metabolic dysfunction on treatment outcomes and learn more about the companys lead compound SDX-7320.Laura Lansdowne (LL): Could you tell us about the link between cancer and metabolic hormone dysfunction?Jim Shanahan (JS): It is commonly understood that obesity increases the risk for certain cancers. What drives this effect has to do with adipose (fat) tissue, which produces a variety of hormones and cytokines that, when dysregulated (as in obesity), stimulate tumor growth and metastasis. Two of the most common and potent metabolic drivers of cancer are insulin and leptin.Insulin, produced by the pancreas in response to elevated blood glucose, stimulates tumor growth via the PI3K/Akt/mTOR pathway. Insulin resistance, often seen in people who are obese or even simply those who have excess visceral adipose tissue (i.e., belly fat) is a pathological state where peripheral tissues (i.e., liver, adipose tissue, skeletal muscle) are less responsive or unresponsive to insulin, leading to chronically high levels of fasting insulin. In the US, an estimated 88 million people have insulin resistance and in the UK, an estimated 12 million are at risk for Type 2 diabetes. This is not a new problem; almost 20 years ago, Dr Pamela Goodwin, a leader in the field, reported that High levels of fasting insulin identify women with poor outcomes in whom more effective treatment strategies should be explored. A large recent study of > 20,000 post-menopausal women showed a significantly increased risk of cancer-specific mortality with elevated insulin resistance. Despite the abundance of research showing insulin is a bad actor in cancer, insulin levels are rarely ever measured in cancer patients.Leptin is an adipocyte-derived hormone whose levels are in direct proportion to fat mass. Leptin acts as a primary regulator of normal metabolic physiology and energy metabolism. The binding of leptin to its specific receptor activates multiple signaling pathways, including the Janus kinase 2(JAK2)/ signal transducer and activator of transcription 3 (STAT3), insulin receptor substrate (IRS)/phosphatidylinositol 3 kinase (PI3K), SH2-containing protein tyrosine phosphatase 2 (SHP2)/mitogen-activated protein kinase (MAPK) and 5' adenosine monophosphate-activated protein kinase (AMPK)/ acetyl-CoA carboxylase (ACC), in the central nervous system and peripheral tissues. Importantly many of these pathways are validated oncogenic pathways commonly targeted by cancer drugs since they overlap with growth factor signaling (e.g., VEGF and bFGF, Her2). More recently it was found that leptin receptors are highly expressed on cancer cells and leptin has been shown to increase cell proliferation, inhibit apoptosis, promote angiogenesis and induce anti-cancer drug resistance. These characteristics are associated with a subset of cells in both liquid and solid tumors known as cancer stem cells (CSCs), or tumor-initiating cells, leading to the formation of metastatic lesions.Conversely, in patients with metabolic dysfunction, the secretion of a key protective adipokine called adiponectin, is reduced. Adiponectin increases insulin sensitivity, thereby reducing levels of fasting insulin. Through its receptor interactions, adiponectin may exert its anti-carcinogenic effects including regulating cell survival, apoptosis and metastasis via a plethora of signaling pathways. Adiponectin has also been shown to directly inhibit tumor growth and counter-act the tumor-promoting effects of leptin. Furthermore, levels of circulating adiponectin are inversely associated with survival outcomes in breast cancer.The role that metabolic syndrome and metabolic hormones play in cancer is significant yet frequently ignored and entirely underappreciated.LL: Some anti-cancer drugs can cause metabolic dysfunction what impact does this have on efficacy and overall treatment success?JS: The short answer is that metabolic dysfunction (independent of origin) has a decidedly negative impact on treatment outcomes and patient quality of life. Many common anti-cancer treatments induce insulin resistance, obesity, Type 2 diabetes and metabolic syndrome, such as doxorubicin, Taxol, platinum-based drugs, aromatase inhibitors, gonadotropin-releasing hormone agonist as well as newer targeted therapies, such as the PI3K inhibitor Piqray (alpelisib, Novartis), mTOR inhibitors and steroids among others. What is emerging is an understanding that these treatment-induced metabolic complications blunt the impact of the anti-cancer treatment itself and can even cause treatment resistance. Hyperglycemia and the subsequent hyperinsulinemia are common in cancer treatment. Yet, insulin levels, which are highly stimulative to many cancers, are rarely monitored and therefore rarely treated. Its an oversight in clinical practice that needs to be remedied urgently.LL: How can metabolic dysfunction and cancer growth be counteracted pharmacologically?JS: At the moment, there are no drugs for targeting tumors sensitive to metabolic hormones. This is the gap in cancer treatment we are targeting with our lead drug SDX-7320. As a stopgap, many oncologists give their patients metformin, as it has been shown to have a modest effect on cancer treatment-induced metabolic dysfunction and may even improve cancer outcomes. Occasionally, oncologists refer their cancer patients to endocrinologists for more acute metabolic care via anti-diabetic drugs like SGLT2 inhibitors. While these anti-diabetics may have clinical utility in helping control hyperglycemia, they generally have only a modest effect on hyperinsulinemia/insulin resistance or high circulating leptin levels. As difficult as they are to maintain, diet and exercise are still the best weapons in the battle against cancer treatment-induced metabolic dysfunction.LL: Can you tell us more about the companys lead compound SDX-7320, in terms of its design, mechanism of action, the indications it is being investigated for and the clinical programs currently underway?JS: SynDevRxs lead compound is SDX-7320 a polymer-drug conjugate consisting of a small molecule MetAP2 inhibitor attached via a peptide linker to a high molecular weight polymer backbone. SDX-7320 is itself inert, but in vivo, the pharmacologically active small molecule fumagillol-derivative is released from the polymer/peptide linker upon contact with lysosomal enzymes. The concept behind the drugs design was to improve the safety profile of the active small molecule by preventing it from crossing the bloodbrain barrier a known and challenging side effect of MetAP2 inhibitors. Another objective of the polymer-conjugation approach was to improve its drug-like properties, as fumagillin is unstable and poorly soluble.The active small molecule is based on fumagillin, a natural product isolated from the fungus Aspergillus fumigatus Fresenius. Fumagillin and its derivatives are potent and selective inhibitors of the enzyme, MetAP2. Covalent modification of MetAP2 by the fumagillin pharmacophore not only inhibits the aminopeptidase activity of MetAP2, but also results in decreased turnover and thus the accumulation of the inhibited protein. This results in multiple beneficial downstream effects including cell cycle arrest, modified angiogenic growth factors, improvements to the tumor immune micro-environment and amelioration of dysregulated metabolic hormones.The polymer conjugation technology yields a number of advantages of SDX-7320 over traditional small molecule fumagillin-based MetAP2 inhibitors, for example dramatically superior water solubility, excellent stability, and a highly favorable PK profile which allows for a patient-friendly dosing schedule and administration by subcutaneous injection a first for a polymer-drug conjugate. Additionally, the high average molecular weight of SDX-7320 has proven effective at minimizing the historic, class-specific CNS adverse effect observed with small-molecule fumagillin analogs.Interestingly, our expectations for the polymer-drug conjugate were that we would see absolute doses increase significantly, with respect to the small molecule doses. Decades of polymer-drug conjugation research suggested doses should increase by as much as 10x (compared to the small molecule) with little to no change in safety. In fact, we saw the opposite. In multiple head-to-head experiments, we saw greater activity with lower doses of the conjugate (in absolute drug weight terms) compared to the small molecule and with a better safety profile.SDX-7320 is being developed for the treatment of cancers that are sensitive to metabolic hormones, with our first indication being breast cancer. A Phase 1 trial of SDX-7320 was completed in 2020, in patients with advanced solid tumors. The results of this trial defined the recommended Phase 2 dose and schedule as well as demonstrated favorable effects on metabolic and angiogenic biomarkers. Clinical trials are planned in combination with standards of care in triple-negative breast cancer (TNBC) as well as in ER+/Her2- breast cancer in combination with a PI3K inhibitor (Piqray/alpelisib) in patients with a PIK3CA mutation.Jim Shanahan was speaking with Laura Elizabeth Lansdowne, Senior Science Writer for Technology Networks.

Read more here:
The Link Between Cancer and Metabolic Dysfunction - Technology Networks

STOCKHOLM, Dec. 16, 2020 /PRNewswire/ -- Diamyd Medical and the Critical Path Institute (C-Path) are proud to announce their collaboration to significantly improve the scientific community's insight into type 1 diabetes (T1D) through Diamyd Medical's contribution of fully anonymized data from a European Phase III trial to the Trial Outcome Measures Initiative (TOMI) T1D integrated database.

The Phase III trial evaluated the use of the diabetes vaccine Diamyd, an antigen-specific immunotherapy based on the auto-antigen GAD (glutamic acid decarboxylase), to induce immunological tolerance and stop the autoimmune destruction of insulin producing cells. The Data Contribution Agreement between Diamyd Medical and C-Path will allow for this unique set of fully anonymized clinical trial data to be integrated into an ever-growing list of committed trial data sets within the TOMI-T1D project.

TOMI-T1D is an international partnership between academia, the pharmaceutical industry and nonprofit organizations. It is funded by the world's leading charities dedicated to diabetes research, JDRF, and Diabetes UK, guided by both organizations' strong commitment to facilitate deep interrogation of consolidated community-wide trial data as a means to accelerate clinical research and therapeutic development for T1D. TOMI-T1D aims to create a clinical trial simulation tool (CTST) with large and diverse clinical datasets from the T1D community. The project also seeks to engage the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to identify opportunities for regulatory endorsement of such drug development tools.

The Diamyd Medical data includes relevant information about disease progression, drug effects and clinical trial design. Contribution of these robust data sets from industry led trials is critical to TOMI-T1D's work in developing innovative and quantitative tools that can facilitate clinical development efforts and be endorsed by regulators for future use by the pharmaceutical industry to optimize the design of future clinical trials.

"Progress towards the establishment of approved therapies for people with T1D is critically reliant on participation from our partners in industry with their data", said Simi Ahmed and Elizabeth Robertson, on behalf of the charity partnership.

"This is indeed a right step in that direction", said Colin Dayan, lead PI at Cardiff University.

"We are thrilled that Diamyd Medical is taking a leading role and championing precompetitive collaborations advancing type 1 diabetes regulatory science solutions", said Inish O'Doherty Executive Director at C-Path. "Their data will help in the construction and evaluation of a clinical trial simulation tool to assist in the development of novel therapies for type 1 diabetes patients".

"We are very honored to be part of this important collaboration -involving key stakeholders within the type 1 diabetes landscape, said Ulf Hannelius, President & CEO of Diamyd Medical. "As we are moving into an era of precision medicine in type 1 diabetes, we can expect to see significant therapeutic advances, and access to high quality data will be integral to maximizing these efforts".

To learn more about the TOMI-T1D project visit: https://c-path.org/programs/tomi-t1d/

About Critical Path Institute

Critical Path Institute (C-Path) is an independent, nonprofit organization established in 2005 as a public and private partnership. C-Path's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established numerous global consortia that currently include more than 1,600 scientists from government and regulatory agencies, academia, patient organizations, disease foundations, and dozens of pharmaceutical and biotech companies. C-Path US is headquartered in Tucson, Arizona and C-Path, Ltd. EU is headquartered in Dublin, Ireland, with additional staff in multiple other locations. For more information, visit c-path.org and c-path.eu.

About JDRF

JDRF's mission is to accelerate life-changing breakthroughs to cure, prevent, and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact and uniting on a national stage to pool resources, passion and energy. We collaborate with academic institutions, policymakers and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF

About Diabetes UK

1. Diabetes UK's aim is creating a world where diabetes can do no harm. Diabetes is the most devastating and fastest growing health crisis of our time, affecting more people than any other serious health condition in the UK - more than dementia and cancer combined. There is currently no known cure for any type of diabetes. With the right treatment, knowledge and support people living with diabetes can lead a long, full and healthy life. For more information about diabetes and the charity's work, visit http://www.diabetes.org.uk

2. Diabetes is a condition where there is too much glucose in the blood because the body cannot use it properly. If not managed well, both type 1 and type 2 diabetes can lead to devastating complications. Diabetes is one of the leading causes of preventable sight loss in people of working age in the UK and is a major cause of lower limb amputation, kidney failure and stroke.

3. People with type 1 diabetes cannot produce insulin. About 10 per cent of people with diabetes have type 1. No one knows exactly what causes it, but it's not to do with being overweight and it isn't currently preventable. It's the most common type of diabetes in children and young adults, starting suddenly and getting worse quickly. Type 1 diabetes is treated by daily insulin doses - taken either by injections or via an insulin pump. It is also recommended to follow a healthy diet and take regular physical activity.

4. People with type 2 diabetes don't produce enough insulin or the insulin they produce doesn't work properly (known as insulin resistance). Around 90 per cent of people with diabetes have type 2. They might get type 2 diabetes because of their family history, age and ethnic background puts them at increased risk. They are also more likely to get type 2 diabetes if they are overweight. It starts gradually, usually later in life, and it can be years before they realise they have it. Type 2 diabetes is treated with a healthy diet and increased physical activity. In addition, tablets and/or insulin can be required.

For more information on reporting on diabetes, download our journalists' guide: Diabetes in the News: A Guide for Journalists on Reporting on Diabetes (PDF, 3MB).

About Diamyd Medical

Diamyd Medical develops therapies for type 1 diabetes. The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined patient group in a large-scale metastudy as well as in the Company's European Phase IIb trial DIAGNODE-2, where the diabetes vaccine is administered directly into a lymph node in children and young adults with newly diagnosed type 1 diabetes. A new facility for vaccine manufacturing is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd. Diamyd Medical also develops the GABA-based investigational drug Remygen as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB.

Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser; phone: +46 8-528 00 399, e-mail: info@fnca.se

CONTACT:

For further information, please contact:

Ulf Hannelius, President and CEO

Phone: +46 736 35 42 41

E-mail: ulf.hannelius@diamyd.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/diamyd-medical-ab/r/diamyd-medical-and-critical-path-institute-announce-data-sharing-collaboration-to-develop-advanced-d,c3255392

The following files are available for download:

View original content:http://www.prnewswire.com/news-releases/diamyd-medical-and-critical-path-institute-announce-data-sharing-collaboration-to-develop-advanced-drug-development-tools-in-type-1-diabetes-301193791.html

SOURCE Diamyd Medical AB

Company Codes: Frankfurt:DMN, ISIN:SE0005162880, Munich:DMN, Stockholm:DMYD, Stockholm:DMYD-B.ST

Originally posted here:
Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes -...

Adroit Market Research published a new research report of Global Opthalmology Pacs Market 2020-2026 presents a widespread and elementary study of the market including key business insights and the analysis of subjective views related to the market. The global Opthalmology Pacs market report examines the market position and viewpoint of the market worldwide, from various angles, such as from the key players point, geological regions, types of product and application. This Opthalmology Pacs report highlights the key driving factors, constraint, opportunities, challenges in the competitive market. It also offers thorough Opthalmology Pacs analysis on the market stake, classification, and revenue projection. The Opthalmology Pacs market report delivers market status from the readers point of view, providing certain market stats and business intuitions. The global Opthalmology Pacs industry includes historical and futuristic data related to the industry. It also includes company information of each market player, capacity, profit, Opthalmology Pacs product information, price, and so on.

The report includes the most important industry information while highlighting vital and valuable data. The report provides learning of various factors such as Opthalmology Pacs market growth, consumption volume, market trends, and business price structures throughout the forecast amount from 2020 to 2026. A detailed study report is accessible for the beneficial of audience and stakeholders. It studies the market dynamic factors including the drivers, restraints, trends, and opportunities of the global market. The report also analyze the competitive landscape of the business. Opthalmology Pacs Market is growing at high CAGR during the forecast period 20212027. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get the PDF Sample Copy of this report @ https://www.adroitmarketresearch.com/contacts/request-sample/608?utm_source=PT

Highlights of The Global Opthalmology Pacs Market Report: A clear understanding of the Opthalmology Pacs market supported growth, constraints, opportunities, encountered challenges, technological advancements, practicable study. The market review for the global market is done in context to region, share, and size. Analysis of evolving market segments in addition to a complete study of existing market segments. The performance of the market throughout 2020-2026 is being forecasted during this report. The data has been categorized and summarized based on types, regions, companies, and applications of the product. The report has examined cutthroat developments such as agreements, expansions, new product launches, and mergers in the market

Global Opthalmology Pacs market is segmented based by type, application and region.Based on Type, the market has been segmented into:

By End-Use, market is segmented into:

HospitalsAmbulatory Surgical Center (ASCS) & Specialty ClinicsOthersBy Type, market is segmented into:

Standalone PACSIntegrated PACSBy Delivery Model, market is segmented into:

Cloud/ web based modelsOn-premise modelsOthers

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/opthalmology-pacs-market?utm_source=PT

Top Leading Key Players are:

Topcon Corporation, IBM corporation, Carl Zeiss Meditec AG, EyePACS, Heidelberg Engineering and more.

This detailed report also highlights key insights on the factors that drive the growth of the market as well key challenges that are expected to hamper the market growth in the forecast period. Keeping a view to provide a holistic market view, the report describes the market components such as product types and end users in details with explaining which component is expected to expand significantly and which region is emerging as the key potential destination of the Opthalmology Pacs market. Moreover, it provides a critical assessment of the emerging competitive landscape of the manufacturers as the demand for the Opthalmology Pacs is projected to increase substantially across the different regions.

Key Questions Answered in the Report:1. What is the size of the overall Opthalmology Pacs market and its segments?2. What are the key segments and sub-segments in the market?3. What are the key drivers, restraints, opportunities and challenges of the Opthalmology Pacs market and how they are expected to impact the market?4. What are the attractive investment opportunities within the Market?5. What is the Opthalmology Pacs market size at the regional and country-level?6. Who are the key market players and their key competitors?7. Market value- chain and key trends impacting every node with reference to companies8. What are the strategies for growth adopted by the key players in Opthalmology Pacs market?9. How does a particular company rank against its competitors with respect to revenue, profit comparison, operational efficiency, cost competitiveness and market capitalization?10. How financially strong are the key players in Opthalmology Pacs market (revenue and profit margin, market capitalization, expenditure analysis, investment analysis)?11. What are the recent trends in Opthalmology Pacs market? (M&A, partnerships, new product developments, expansions)

Table of Content:1. Industry Overview of Opthalmology Pacs.2. Manufacturing Cost Structure Analysis of Opthalmology Pacs market.3. Specialized Information and Manufacturing Plants Investigation of Opthalmology Pacs.4. Capacity, Production and Revenue Analysis.5. Price, Cost, Gross and Gross Margin Analysis of Opthalmology Pacs by Regions, Types and Manufacturers.6. Consumption Volume, Consumption Value and Sale Price Analysis of Opthalmology Pacs industry by Regions, Types and Applications.7. Supply, Import, Export and Consumption Analysis of Opthalmology Pacs Market.8. Major Manufacturers Analysis of Opthalmology Pacs industry.9. Marketing Trader or Distributor Analysis of Opthalmology Pacs.10. Industry Chain Analysis of Opthalmology Pacs.11. Development Trend Analysis of Opthalmology Pacs Market.12. New Project Investment Feasibility Analysis of Opthalmology Pacs.13. Conclusion of the Opthalmology Pacs Industry.

For Any Query on the Opthalmology Pacs Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/608?utm_source=PT

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read the rest here:
Opthalmology Pacs Market Global Innovations, Competitive Analysis, New Business Developments and Top Companies Global Forecast to 2026 - LionLowdown

In a bid to give access to health services to people belonging to every strata of the society, December 12 is celebrated as the Universal Health Coverage Day all across the world. The theme of 2020 is Health for all: protect everyone. To end this crisis and build a safer and health systems that protect us all now. Ayushman Bharat Pradhan Mantri Jan Arogya Yojana is the Government of Indias attempt in the direction of Universal Health Coverage and it bridges the gender gap by providing access to healthcare services to women. It is to be noted that of all the hospital admissions, 49.8% of the treatment(insights.pmjay.gov.in) hasbeen availed by women.

The 2018 Gender Gap Index of the World Economic Forum and its sub-index, Health and Survival ranked India at 108th position in the overall index and 147th out of 149 in the sub-index. Here is how Ayushman Bharat PM-JAY is empowering women in accessing healthcare services

* Families with no adult male members is one of the deprivation criteria foridentifying target beneficiaries, which will ensure the reach of the scheme to a large number of women.

* Cap of five beneficiaries from a family in earlier schemes worked against women. It was seen that families prefer to prioritise the male members over females, excluding them from availing free health care benefits. Ayushman Bharat PM-JAY does not have any ceiling on number of family members hence the right to free healthcare under the scheme is being equally exercised by male and female members of the family.

* Being a man or a woman has significant impact on health due to biological and gender related differences. The packages include a large number of health conditions that exclusively, or primarily, affect women.

* Under Ayushman Bharat, individual e-cards are being issued which gives every female beneficiary an individual sense of entitlement to claim their right to free healthcare.

Women-specific DATA points:

* Top 5 states, where women are availing higher number of treatments:

1. Tamil Nadu

2. Kerala

3. Chhattisgarh

4. Karnataka

5. Andhra Pradesh

* Top 5 specialities availed by women:

1. General Medicine

2. Obstetrics & Gynaecology

3. General Surgery

4. Medical Oncology

5. Opthalmology

6. Infectious Diseases

A lot of beneficiaries feel grateful to have been given a new lease on life and resident of Gurgaon, Santosh is one of them. Aged 44, she, her three children and her ageing in-laws were all dependent on her husband, whose sudden demise further threw the family into distress. Santosh took up the baton, where her husband left off and filled the void. The family slowly began healing and on the road to recovery. Just when things were getting back to normal, Santosh noticed that she was finding it hard to climb up and down the stairs.

However, a sense of sacrifice and service prevented her from doing anything about it. Besides, she did not want to cause anxiety in the family again. She continued as if nothing had happen, hiding her pain and discomfort and turning a blind eye to her condition.

Soon, she got to know about Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY); Haryana Health Protection Mission and the various benefits that were available under this health scheme. Since, her pain was becoming unbearable, she decided to go to a hospital and get checked. She found out that she had two blocked valves in her heart and needed immediate surgery. This timely intervention truly saved her and helped her secure the future of her children.

Besides bridging gender gap, PM JAY has been immensely successful in providinghealthcare services to the needy. As per the latest government data, 1.4 crore cashless treatments worth INR. 17, 535 crores across 24,653 (Public: Private = 54:46) empaneled hospitals have been approved under the scheme. Also, the scheme is at the forefront of battling the pandemic right now. Currently, the COVID 19 testing and treatment numbers are 10,23,651.

See Zee Business Live TV Streaming Below:

Read the rest here:
Universal Health Coverage Day: Nearly 50% of the treatments under PMJAY are availed by women! - Zee Business

Milestone Scientific Inc (NYSEAMERICAN: MLSS) is a medical device research and development (R&D) group.

It designs and patents innovative injection technology and specializes in dynamic pressure sensing, which allows medics to know what the pressure at the tip of needle is at any time.

The company is advancing computer-controlled drug delivery systems that offer significant efficiency and patient comfort gains in the medical and dentistry fields.

Its wand product for dentistry, which is the group's biggest revenue earner, makes an injection at the dentist a lot more comfortable. The numbness is contained on a single tooth rather than a whole portion of the mouth.

In the medical solutions space, the firm has a CompuFlo Epidural Instrument for epidural injections, which has a 99% success in locating the epidural space on the first attempt. Done manually, the procedure can be cumbersome and time-consuming. The company believes the epidural system will become the new standard of care.

The addition to the system (for catheter patients) is its CathCheck technology which is also gaining traction.

Milestone also has a Compuflo training product to help medical students master epidurals. Milestone's CompuFlo Intra-Articular Instrument has been proven successful in administering medicaments into the intra-articular space.

The group is also looking at future products in the cosmetic surgery, opthalmic and neurosurgical sectors.

In a statement at the end of November, the group's president Arjan Haverhals said the firm's dental business continued to recover and he saw growth in dental sales during the fourth quarter of 2020.

"While we are not back to pre-pandemic levels, I am pleased to report our sales continue trending in the right direction and we anticipate revenue in the fourth quarter of 2020 to be a minimum of $1.7 million," he said.

Haverhals said such a haul in revenue would represent a 40% sequential increase versus the 3Q, which follows a 718% increase for the 3Q compared to the 2Q of 2020. And this does not include recent sales to the companys Chinese distributor of about $450,000, which will be recorded as revenue when the inventory is resold by the distributor.

We are encouraged by the current trends in both the USA and around the world, which has improved our cash flow and provides us greater financial stability along with the necessary funds for marketing and sales to continue the growth in the dental sector, he told investors.

Earlier last month, the group posted third quarter financials (to September 30), which showed revenue of $1.2 million compared to the $1.9 million it posted in the same quarter in 2019. The net loss was narrowed to $1.5 million, or $0.02 per share, versus the $2.8 million, or $0.06 a share, it posted in the comparable year-ago quarter.

In October, Milestone was awarded a group purchasing agreement with Premier, a leading group purchasing organization, with around 4,100 US hospitals and 200,000 other providers within its network.

Milestoneis also expanding its trials in major hospitals and medical schools and partnering with key opinion leaders to approach the purchasing departments of hospitals together

The company ended the three-month period with over $14 million of cash on hand, which will support marketing and other ongoing activities, it added.

President Arjan Haverhals spoke to Proactive in November this year and said the company was in good financial shape with no plans to raise capital in the short, or mid-term.

"With the cash at hand, the recovery of the dental business, we have a burn rate of about US$320,000 per quarter, and hen also with the anticipated sales of the CompuFlow, the epidural system, and the CathCheck, we really look forward to become cash positive next year."

Contact the author at [emailprotected]

The rest is here:
Milestone Scientific, the pressure sensing specialist, has cash in bank and eyeing growing dental sales - Proactive Investors USA & Canada

NHS Lothian revealed yesterday it had been informed that despite an agreement in 2018, the government was not in a position to fund a replacement for Edinburghs Princess Alexandra Eye Pavilion now or in the foreseeable future.

At First Ministers Questions, Lothian Conservative MSP Miles Briggs said: Plans for a replacement for the 50 year-old Eye Pavilion were at an advanced stage and contracts were awarded some two years ago. Will the First Minister personally intervene today and restore this vital funding for our NHS?

Ms Sturgeon said she was not sure the situation was quite as Mr Briggs had described. But she said she would look into it further and write to him.

She added: As is the case for governments across the UK, funding is constrained, we have to make difficult choices about funding but making sure we have fit-for-purpose, state-of-the art health facilities in every part of the country is a priority.

The new hospital was planned to be located close to the Royal Infirmary at Little France, replacing the existing pavilion in Chalmers Street, which was opened in 1969. The current building was deemed unfit for purpose several years ago.

In an email to key groups yesterday, NHS Lothian opthalmology programme manager Kathleen Imrie said in 2018 the health board had been invited by the Scottish Government to prepare an outline business case, hew hospital design plans were developed and the business case was submitted in May 2019.

We have now received the formal response from the Scottish Governments which is that unfortunately, they are not in a position to fund a new Eye Hospital now or in the foreseeable future.

I am sure you will share our disappointment at this news, especially given the enthusiasm and commitment shown by yourselves as service users, carers, and partner organisations and staff in progressing the design in support of the business case.

Despite this setback, delivery of safe, effective and efficient eye care, remains a key priority for NHS Lothian. Alternative accommodation options will be looked at, including a review of feasible modern service models. The input from service users and the significant multi-professional redesign work undertaken to date will act as a solid foundation for this.

After the festive period we will re-group to agree how we now move forward.

Mr Briggs said it was totally unacceptable that the government had refused funding for the re-provision of the Princess Alexandra Eye Pavilion.

NHS Lothian have made it clear to SNP ministers that a new eye hospital is urgently needed in Lothian.

SNP ministers have received record funding from the UK government for our health service, which they have mismanaged and not used on vital services such as a new Princess Alexandra Eye Pavilion hospital.

For too long SNP ministers have underfunded NHS Lothian and it is now clear that patients are paying the price.

A message from the Editor:

Thank you for reading this article. We're more reliant on your support than ever as the shift in consumer habits brought about by coronavirus impacts our advertisers.

Read the original here:
Plea to Nicola Sturgeon after Scottish Government withdraws funding for Edinburgh's new eye hospital - Edinburgh News

In this episode, were all about regeneration. We talk with a Tufts biologist about the ways some animals regrow lost body parts, and the real possibility of science helping humans do the same one day. An ecologist explains how forests have the capacity to recover from even the most devastating wildfiresan ability theyve honed over thousands of years.

We hear how some species have come back from near extinction with a little attention from their human counterparts, and some enthusiastic farmers show that even something as basic as dirt can come alive with the right care. We share one experts vision for growing a better, greener economy in the wake of the pandemic, before taking a detour for the tale of some long-lost paintings given a second chance for appreciation.

Finally, we talk with an alumna who suffered a great physical loss, but went on to build a new career and a new outlook for herself. As she says, Theres always an opportunity for renewal.

Subscribe toTell Me MoreonApple Podcasts,Google Play Music,Spotify,Stitcher, andSoundCloud.

Read the Full Transcript

Read More About Regenerative Medicine

Michael Levin, A92, is the director of the Allen Discovery Center at Tufts University and the Tufts Center for Regenerative and Developmental Biology. He is also Vannevar Bush Professor and Distinguished Professor of Biology. Read about frogs starting to regrow limbs, tadpoles prompted to grow extra eyes, and some other recent research from his lab on Tufts Now.

Michael Reed, professor of biology, studies avian ecology and conservation biology. He looks at how habitat loss and fragmentation affect extinction risk and population viability, as well as the role of animal behavior in extinction risk and conservation.To get a feel for why species regeneration is so urgent, read about the UN report on species extinction rates, the report on species population size decline, and the 3 billion North American birds that have vanished since 1970.

Erica Smithwick, J95, majored in geology and environmental studies at Tufts. She is now a professor of geography at Penn State, where she is director of the Ecology Institute. A landscape and ecosystem ecologist, she is involved in understanding how a wide range of disturbances, especially fire, affect ecosystem function.

Rachel Kyte is the dean of The Fletcher School. A 2002 graduate ofFletchers Global Master of Arts program, Kyte served as special representative of the UN secretary-general and chief executive officer ofSustainable Energy for All. Previously, she was the World Bank Group vice president and special envoy for climate change. Read more about her call for a green recovery in the New York Times.

Meghan Powers and Elliot Rossow started their cultivation careers through a course with the New Entry Sustainable Farming Project at the Friedman School of Nutrition Science and Policy, later applying for a plot of land through NESFPs incubator program. They now run Kona Farms as a living laboratory for environmental stewardship. Reach them at konafarmsma@gmail.com or on Instagram.

Christina Maranci is chair of the department of history of art and architecture in the School of Arts and Sciences. She is also the Arthur H. Dadian and Ara Oztemel Professor of Armenian Art and Architecture. Maranci's research is mainly onmedieval Armenian history and the relationship with the Sasanian, Byzantine, and Islamic empires. See some of her photos of the art of Ani Cathedral on Tufts Now.

Maggie Baumer, A04, studied clinical psychology at Tufts before graduating from law school. She manages the Springfield, Mass., location of Hanger Clinic, the nations largest provider of state-of-the-art prostheses. She is also a certified peer visitor for theAMPOWER program, a peer-to-peer network designed to empower and strengthen those affected by amputation or limb difference.

Transcript

JULIE FLAHERTY: 2020 has been a really rough year, which is why everyone is hoping that a new year will bring brighter times.

ANNA MILLER: And that got us thinkingabout renewal, about starting over, about rising from the ashes. This is Tell Me More, the Tufts University podcast. Im Anna Miller.

FLAHERTY: And Im Julie Flaherty. In this episode, were all about regeneration. Were talking forests that bounce back after massive wildfires, animals that regrow lost limbs, and people who manage to rebuild their lives after calamity.

MILLER: They are just the kind of inspiring stories we need right now.

FLAHERTY: If you want to be encouraged about the possibility of regeneration, just talk to Michael Levin. Levin is the director of the Allen Discovery Center at Tufts and the Tufts Center for Regenerative and Developmental Biology. I asked him about the most impressive examples of regeneration he knows.

MICHAEL LEVIN: Many people know about things like the axolotl, which is a salamander that will regenerate almost any organ. So they regenerate their eyes, their jaws, their limbs, their ovaries, portions of their brain and heart. But some other cool ones are, for example, deer. So deer are a large adult mammal, and every year they regenerate their antlers. And antlers have bone and skin and vasculature and nerve, and they will regenerate those antlers at a rate of about a centimeter and a half per day. So think about that. Every day, that thing adds a centimeter and a half of new bone.

FLAHERTY: But even more impressive might be a creature Levin uses in a lot of his worka little guy called the flatworm.

LEVIN: Well, the planaria, the flatworms are an amazing model system. They combine most of the interesting problems of biology are found in this animal. Its just remarkable. First of all, they regenerate from any piece of the body. The record, I think is something like 275 pieces. You can cut the worm in any way you want. Every piece knows exactly what a correct worm looks like, and it will build exactly whats needed, no more, no less, to give you a tiny, perfect little worm. So they hold the secret to regeneration. So thats the first thing.

The second thing is theyre also immortal. They have no lifespan limits. So theres no such thing as an old planarian. They live forever, and thats telling us that in fact aging is not an inescapable part of life. These animals have been with us for probably 400 million years. And these are the exact same worms. They just do not age. So thats telling us that immortality is possible for a complex creature.

FLAHERTY: Thats all very well for the worms. But what about people?

LEVIN: The other thing a lot of people may not know is that even human children can regenerate their fingertips. So somewhere between the age of 7 and 11, most of us lose this. There used to be more of this back in the 70s, when fans werent covered with the metal grates and everything. But a clean amputation of a digit for a small child usually just grows back perfectly.

FLAHERTY: No one knows for sure why we lose the ability to regenerate as we get older. But Levin says that all of the information for how to do it is still inside us. We just need to figure out how to turn it back on. And Levin thinks it has something to do with bioelectricity, the flow of ions between cells in the body. Thats how cells communicate with each other.

Levin, who studied both biology and computer science as an undergrad at Tufts, likens it to software. If we can find the code that the cells use to communicate about regeneration, we can run that program, and get the cells to do the work of building a new finger or what have you.

LEVIN: So all of those kinds of computations, when the cells join together to say, what should we be building? Are we done yet? Is there a finger missing? How many fingers should there be? That kind of thing. All of that is mediated electrically.

So if we understood how that worked, we could artificially inject electrical information to get the cells to do whatever we wanted them to do. And so this means kickstart a normal regenerative cascade, or reprogram a tumor into normal tissues, or build a completely new anatomical structure thats never been seen before, some sort of synthetic living device. All of that is possible if we understand how cells cooperate towards these kinds of outcomes.

What weve developed are some of the first tools to listen in on, and then modify, the natural electrical conversations that cells are having with each other. We basically go in and we open and close the ion channels that are in those cells, to modify how they talk to each other.

FLAHERTY: Levins lab has conducted many groundbreaking experiments over the years. They have coaxed a mature frog, which typically does not have the ability to regenerate its limbs, to begin to grow a new leg. Another experiment involved convincing a tadpole to grow an eye. But they didnt want the eye in the usual place.

LEVIN: We observed that there was a special electrical pattern that was present in the embryo where the eye was going to form. So what we simply did was reproduce that same pattern somewhere else. What we found is that, sure enough, the cells know that that pattern means make an eye here. And if you make that electrical distribution in the gut, then you will have an eye in the gut, and if you make it in the tail, you will have an eye in the tail.

FLAHERTY: Yes, a tadpole with eyes on its tail is weird, but it showed something important. To use that software analogy again, it showed that cells can be reprogrammed. You dont have to rewire the hardware to make an eye.

LEVIN: We dont know how to make an eye ourselves. The eye has many different cell types, arranged in a really exquisite pattern. We cant reproduce any of that by hand. Its way too complex. But we found that with a very simple trigger, the whole eye is formed. So that told us that theres a path towards regenerative medicine where you dont need to try to micromanage the whole process. You need to find the logic of the natural software thats being used, and you can take advantage of it.

FLAHERTY: Levin believes that one day, humans are going to be able to regrow eyes, limbs, hearts, and other useful things.

And you think youre going to see this happen in your lifetime?

LEVIN: I hope I not only to see it happen, I hope I help make it happen. Were working very hard towards this now. Im optimistic. I think were going to see amazing things out of regenerative medicine in the next decade or two.

MILLER: So some animals are pretty good at regenerating body parts. But what happens when a whole group of animals is threatened with extinction? Is there any way to regrow a species? We put that question to someone who studies animal populations.

MICHAEL REED: My name is Michael Reed, Im a professor in the biology department at Tufts University.

MILLER: There is an urgency behind this question. Right now, were in an environmental crisis. And a lot of animals are disappearing.

REED: Were now moving into a sixth mass extinction thats, if continued, would build to be similar to one of the mass extinctions during geologic time, the last of which was the disappearance of most of the dinosaurs.

MILLER: This time, theres no meteor. Instead, its us. Simply put, our actions are killing animals around the globe in shocking numbers. Since the 1970s, 68 percent of all animal populations have been wiped out.

REED: If you were paying attention to the news a year ago, you would have seen around the world headline news of 3 billion birds lost in North America.

MILLER: A report delivered by the United Nations estimates that within the next 30 years, anywhere from a third to half of all species on the planet might go extinct. So what are humans doing to cause this? Its climate change, its wildlife trafficking, its use of pesticidesbut the biggest killer, says Reed, these animals have run out of places to live.

REED: The number one problem globally is habitat loss, habitat fragmentation, and degradation of habitat. If you take away a species habitat, the species doesnt exist anymore.

MILLER: So can we even turn this around? I asked Reed if he knows of a species that people have successfully brought back from the brink of extinction.

REED: Yeah. Fortunately there are examples, otherwise I think people would give up in despair.

We kept bison from going extinct in the U.S. Theyre not anywhere near the numbers they were at one time. There used to be hundreds of millions of them and their range actually extended into the middle of New York state. In Pennsylvania you could see bison. Their numbers are extremely low compared to that. But since we were down to dozens, I think the tens of thousands we have now is pretty good. So at that stage, it depends on exactly how youre defining success.

MILLER: When we stopped using the pesticide DDT, which turned out to be damaging to eggs, some bird species bounced back.

REED: The bald eagle has moved off of the endangered species list. The peregrine falcon has moved off the endangered species list. Osprey are returning to many of their haunts on the East Coast of the U.S. and Northern Europe with the cessation of the use of DDT.

Ironically, the one large group of birds thats doing really well, and their numbers are going up instead of down, is waterfowl. And we hunt them. Animals were going out and shooting, harvesting, their numbers are going up, while the animals that were not harvesting are going down. The big difference is for harvested animals, people are putting their money where their mouth is and says, Id like more of them. Lets spend millions of dollars recreating habitat, bolstering populations.

Frankly, any of you who go to national wildlife refuges, those were paid for by duck hunters. Thats why we have these refuges. It demonstrates that with interest and money, we can turn these around really well, even for harvested things. Looking at examples like that gives me a lot of hope.

MILLER: There are simple things people can do to boost wildlife populations.

REED: So if youre cutting down lots of habitat and the species are disappearing, quit wrecking so much habitat, or find ways to leave patches behind that are sufficient for species or corridors that connect one reserve to another reserve. Or in your yard, instead of having a bunch of grass, let some wildflowers grow and bring back native pollinators.

We have proven that we have the capacity to make a difference and to turn things around and that it just requires some awareness and some thoughtfulness.

FLAHERTY: We humans can take all the blame for habitat loss. But sometimes destruction and regeneration are just part of the natural cycle.

Erica Smithwick has made a career studying how ecosystems recover from traumas like insect infestations and wildfires. Smithwick, who graduated from Tufts in 1995 and is now a professor of geography at Penn State, has extensively studied the 1988 wildfires in Yellowstone National Park. More than 40 percent of the park was burned, and news accounts at the time made it seem like the park might not survive.

NEWS ANCHOR: Our oldest National Park is under siege tonight...

NEWS ANCHOR #2: The president to declare Yellowstone National Park a national disaster area...

ERICA SMITHWICK: The media coverage at the time was really alarmist. It was talking about the destruction and all these D words, death, destruction, disaster. It really was portrayed in that way. And actually what the science showed us was completely the opposite. And its one of the lessons we learned from studying the Yellowstone landscape over decades, frankly, is that the system recovered, it had the potential to recover.

And if you go to Yellowstone today, you probably wouldnt know that it once was a blackened landscape because its completely green, you see all of the trees coming back, a carpet of trees really just covering the whole landscape. And you have to dig deeper to understand that a lot of that regeneration was because the trees have the capacity to recover from severe fire.

FLAHERTY: In fact, the trees depend on fire to reproduce. They need the heat of a large fire to melt the resin in their pinecones and release seeds of new plants.

SMITHWICK: And it turns out that the lodgepole pine trees that are dominating a lot of the Yellowstone landscapes have this trait because they have adapted to severe fires over the past 10,000 years, the entire quaternary period. Theres memory in the system of these large wildfires. And the fires that occurred in 1988 were basically on cue.

It was about time for one of these large fires. Now, they dont come often, they come every 150 to 300 years. Thats why it wasnt part of our social memory of what the park should be experiencing. But within the context of what we can tell by paleo records of ash and pollen, this was fitting right in with a normal fire cycle of the park.

FLAHERTY: Almost as soon as the fires ended, seedling began to appear. Within a decade, trees rose up, and became what you see now as large mature trees. The recovery was also picturesque, as wildflowers took advantage of newfound sunlight.

SMITHWICK: Fireweed is a particular plant that is very beautiful. Its this purple-pink color and it just is covering the entire understory of the forest. And along with that comes the understory plants that bring nitrogen to the soil. This is a very impoverished nutrient poor ecosystem. And these understory plants bring a lot of nutrients back into the soil.

FLAHERTY Smithwicks research has shown that the fire itself brought a pulse of nitrogen to the soil, in part by breaking down organic matter on the forest floor, making nutrients for the next forest. And as Yellowstone came back, it came back different. Like aspen trees that sprang up where they hadnt been any before. In fact, fires are known for creating biodiversity.

SMITHWICK: Well, this is the thing about disturbances generally in forest city ecosystems is that they do create surprises. They create opportunities for new organisms to persist and even get reintroduced into a certain area.

There are a lot of birds that really enjoy post-fire landscapes or burned landscapes. So black-backed woodpecker would be one Kirtlands warbler in other parts of the U.S. A number of these birds will come into burned environments because the burned ecosystem has lots of cavity in the trees for nesting. And it also has a lot of bugs and beetles. The insects in that forest are actually just presenting a smorgasbord to sunbirds. The sunbirds, they depend on these burned ecosystems for survival, and will seek them out.

FLAHERTY: So forests can recover from massive wildfires. They just need time to do it. And its the lack of time that worries Smithwick right now. These big fires that usually happen hundreds of years apart are now happening every 15 or 30 years.

SMITHWICK: When we see fires like we have in the West, 8.6 million acres burned this year in 2020, and actually five times that amount in the Australian fires, just enormous areas burning. This is out of the realm of what we would expect to be normal. Thats concerning in terms of the ability of those forests to be able to recover.

We want an ecosystem that constantly is renewing itself. We have to learn to live with fire. And we all also have to learn to give our systems time to recover, because they have the capacity to do so.

There is nothing more important right now than fixing the climate situation. And so buying time to do that. And frankly, a lot of the climate work suggests that we do have the potential, if we make the right decisions now, to move the needle and that the earth system, the climate system, will actually respond very quickly.

MILLER: So forests can literally rise from the ashes, and often come back differentmaybe even better. Rachel Kyte, dean of The Fletcher School, thinks that the same is true for economies. Right now, in the midst of the pandemic, economies worldwide are hanging by a string. But Kyte is already thinking about the recovery, and the opportunity it presents to do something for the climate situation Smithwick was just talking about.

RACHEL KYTE: I think its really important to remember that before COVID hit, and I know that feels like a very long time ago, the economy wasnt working for everybody and it wasnt working for the planet.

When we think now about recovery, we have to recover, and through recovery, get ourselves on a trajectory for net-zero emissions by 2050. We have to recover clean and we have to recover in a way that we don't leave people behind. The good news is that thats entirely possible. They are not in opposition to each other.

MILLER: Kyte says that people are going to need jobs, and those jobs could easily be a part of building a greener economy.

KYTE: Whats been interesting through the pandemic is to see that we can agree, the economists worldwide, every international organization that we used to govern the global economy, that there are things that governments can do that will spur short-term income generation, short-term jobs, as well as mid-term growth and long-term emissions reduction.

For example, here in the Northeast of the United States, one of the most important things we could do is massively invest in programs to refurbish, deeply refurbish the built environment. Every time we make a building energy-efficient, those are good, local, skilled, and semi-skilled jobs, we reduce the emissions from this part of the United States, and we build our resilience to the next shocks.

We also know that investing in the infrastructure we need to drive electric cars and hydrogen fuel cells will be important. We also know that investing in the clean energy infrastructure that will allow us to use much more renewable energy will be important. These are good local jobs. Good, local jobs, well-paid put us on a better trajectory and put us on track for zero-net emissions.

MILLER: One way to help reduce carbon emissions is by fixing how we grow food. And thats where something called regenerative farming comes into play. Elliot Rossow is a soil microbiologist. And he cares so much about the earth, he can actually taste it.

ELLIOTROSSOW: Theres this entire classification system of soils and so I can grab some in my hand and put a little bit on my tongue and I can tell you, to a very specific content, how much sand, silt, and clay is in that soil. Which is awesome, its a great party trick.

MILLER:What does good soil taste like?

ROSSOW:Well, no soil really tastes good.

MILLER: Rossow and fellow soil-enthusiast Meghan Powers are incubator farmers with the New Entry Sustainable Farming Projectrun by the Friedman School of Nutrition Science and Policy.

They farm a small plot of land in Beverly, Massachusetts, where they groworganicvegetablesmost of which they donate to charity. But their real aim is figuring out how to bring life back to depleted soil.Heres Powers:

MEGHAN POWERS: So the main purpose of the farm is to test out new and really interesting sustainable management practices and sustainable inputs with the goal of regenerating the land and the soil itself.

MILLER: Why regenerate the land? Powers says the problem is that our agricultural system tends to treat soil like an inert thingput enough chemical fertilizers into it and plants will grow. But chemicals also break down the soil, degrading it. And over time, once you put in enough chemicals, the soil can become unusable.

POWERS:Its really important to start from this holistic perspective that we are working with the soil, and the soil is a living thing.

MILLER: Healthy soil is actually alive with active microbial communitiesmicrobes that help plants and make the soil more resilient. Rossow says you can actually see when dirt is thriving.

ROSSOW:You can definitely feel when soil is alive and intense, and if youve ever played in dirt, played in soil, you notice that it comes in different clumps. Theyre called aggregates, these big clods of dirt you see kids throwing at each other or people break it when they step on them.

But really, the more aggregates and the larger the aggregates means that theres more biological activity happening and flowing through that entire system. And so the more aggregates you have, and the healthier it is, you can see that they kind of grow in size. Whenever were soil sampling out there, and we find it, Oh, my gosh. Look at this one, its as big as my hand. Theyre massive.

MILLER: For the next three years, theyll be using their farm as a living laboratory, testing what works best to produce crops while still making the soil healthy. Because ultimately, healthy soil is a defense against climate change.

POWERS: And the great thing about soil is that you can regenerate it, you can build it back up, its not one and done, you can put carbon back in. And I think thats one of the few solutions that we have really for the climate problem is that we can put carbon in the soil, and we can recharge this system and doing that would take it out of the air and make itmore healthy.Soits really a win-win.

Excerpt from:
Seven Stories of Regeneration | Tufts Now - Tufts Now

Avery Therapeutics is projected to be one of the first companies in the US to seek approval for a clinical trial using iPSC-derived technology for heart failure. The goal of this collaboration is to develop a new off-the-shelf treatment to improve the quality of life of patients suffering from heart failure, a debilitating disease that affects tens of millions of people worldwide.

The iPSCs are manufactured at I Peace's state-of-the-art GMP facility in Kyoto, Japan, under comprehensive validation programs of the facility, equipment, and processes including donor recruiting, screening, blood draw, iPSC generation, storage, and distribution. I Peace has obtained a US-based independent institutional review board (IRB) approval for its process of donor sourcing for commercial-use iPSCs. The facility is designed to be PMDA and USFDA compliant.

As Avery Therapeutics expects to expand the application of its regenerative medicine technology to various types of heart diseases and beyond, iPSCs are the key enabling technology for quality and future scalability. This agreement provides a solid foundation to improve the welfare of those suffering from diseases through advancement of tissue-engineered therapeutics.

"We are thrilled to announce this collaboration with I Peace. It is a big step forward in the development of novel cell-based therapeutics for unmet medical needs. Through this collaboration, I Peace brings deep iPSC development and manufacturing expertise to enable Avery's proprietary MyCardia cell delivery platform technology. Together we hope to positively impact millions of patients worldwide in the near future," Said Jordan Lancaster, PhD, Avery Therapeutics' CEO.

This agreement reflects an innovative collaboration involving multiple locations internationally and marks a significant milestone for both I Peace, Inc. and Avery Therapeutics to pursue one of the first US clinical trials using iPSC technology in the area of heart diseases. Koji Tanabe, PhD, founder and CEO of I Peace stated: "By combining I Peace's proprietary clinical grade iPSC technology and Avery's tissue engineering technology, we can bring the regenerative medicine dream closer to reality. We are very excited by Avery's technology and look forward to continue working together."

About I Peace, Inc

I Peace, Inc. is a global supplier of clinical and research grade iPSCs. It was founded in 2015 in Palo Alto, California, USA by Dr. Tanabe, who earned his doctorate at Kyoto University under Nobel laureate Dr. Shinya Yamanaka. I Peace's mission is to alleviate the suffering of diseased patients and help healthy people maintain a high quality of life by making cell therapy accessible to all. I Peace's state-of-the-art GMP facility and proprietary manufacturing platform enables the fully-automated mass production of discrete iPSCs from multiple donors in a single room. Increasing the available number of clinical-grade iPSC lines allows I Peace customers to take differentiation propensity into account to select the most appropriate iPSC line for their clinical research at significantly reduced cost. I Peace aims to create iPSCs for every individual that become their stem cell for life.

Founder, CEO: Koji TanabeSince: 2015Head Quarter: Palo Alto, CaliforniaJapan subsidiary: I Peace, Ltd. (Kyoto, Japan)Cell Manufacturing Facility: Kyoto, JapanWeb: https://www.ipeace.com

About Avery Therapeutics

Avery Therapeutics is a company developing advanced therapies for patients suffering from cardiovascular diseases. Avery's lead candidate is an allogeneic tissue engineered cardiac graft, MyCardia in development for treatment of chronic heart failure. Using Avery's proprietary manufacturing process MyCardia can be manufactured at scale, cryopreserved, and shipped ready to use. Avery is leveraging its proprietary tissue platform to pursue other cardiovascular indications. For more information visit: AveryThera.com. Follow Avery Therapeutics on LinkedInand Twitter.Since: 2016Headquarter: Tucson, AZWebsite: https://www.AveryThera.com

SOURCE I Peace, Inc.

Read this article:
I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic - PRNewswire

Global Regenerative Medicine Products Market analysis report speaks about the manufacturing process. Global Regenerative Medicine Products market report analyses the market growth, trends, overview & forecast to 2026.The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies.

The research study on Regenerative Medicine Products market boasts of a detailed analysis of this industry vertical, alongside a robust gist of its segmentation. The report is inclusive of a highly viable analysis of the current status of the Regenerative Medicine Products market as well as the market size in terms of the valuation and the volume. Additionally, the research study encompasses a collective summary of vital information with regards to the regional terrain and the companies that have established their stance across this business space.

Request a sample Report of Regenerative Medicine Products Market at:https://www.marketstudyreport.com/request-a-sample/3077558?utm_source=groundalerts.com&utm_medium=SK

Enumerating a rough coverage of the Regenerative Medicine Products market research report:

An in-depth portrayal of the regional landscape of the Regenerative Medicine Products market:

A detailed cover-up of the competitive terrain of the Regenerative Medicine Products market:

Ask for Discount on Regenerative Medicine Products Market Report at:https://www.marketstudyreport.com/check-for-discount/3077558?utm_source=groundalerts.com&utm_medium=SK

A few other takeaways from the research study on the Regenerative Medicine Products market:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-regenerative-medicine-products-market-outlook-2021

Related Reports:

1. Global Small Animal Imaging Reagents Market Outlook 2021Read More: https://www.marketstudyreport.com/reports/global-small-animal-imaging-reagents-market-outlook-2021

2. Global Antioxidant Vitamins Market Outlook 2021Read More: https://www.marketstudyreport.com/reports/global-antioxidant-vitamins-market-outlook-2021

Related Report : https://www.marketwatch.com/press-release/brand-licensing-market-statistics-2020-2025-share-forecasts-trends-growth-drivers-2020-12-15

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See original here:
Latest Study explores the Regenerative Medicine Products Market Witness Highest - GroundAlerts.com

TRUMBULL, Conn., Dec. 15, 2020 /PRNewswire/ --ZetrOZ Systems, developers of the Sustained Acoustic Medicine (SAM) wearable ultrasound, an FDA-cleared bio regenerative medical device, was recently evaluated in a research study published in the Global Journal of Orthopedics Research, which measured the effectiveness of SAM treatment to reduce pain and improve function in athletes in conjunction with traditional therapies following sports-related musculoskeletal injuries. According to the study, the data "confirms the effectiveness of the application of SAM ultrasound in reducing pain as adjunct therapy or standalone therapy."

"The study confirms the effectiveness and benefits for home users, both athletes and non-athletes, who have sustained some kind of musculoskeletal injury," according to Dr. George Lewis, Founder and CEO of ZetrOZ. "The cases referenced in the study indicate SAM's ability to penetrate deep into muscle tissue and provide relief from pain and injury with regular treatment, helping accelerate the healing process and decrease the time it takes to recover."

The study included a case series of 18 professional and collegiate athletes who suffered a musculoskeletal, sports-related injury. The athletes were treated with SAM as supplementary therapy at a specified sports medicine rehabilitation clinic. Regular treatments resulted in 'reduced pain and improved function across numerous muscles, ligament, and tendon conditions.' Most of the athletes in the study were able to return to normal activity, including sports, during their treatment period.

The athletes in the study had previously undergone surgeries or were being considered for surgery. By utilizing sustained acoustic medicine as a long-duration continuous ultrasound therapy, users can accelerate the natural process of healing by inhibiting inflammation, increase the rate of tissue regeneration, angiogenesis, and nutrient exchange.

To read the study in full, visit:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7544191/.

To learn more about ZetrOZ Systems and the company's SAM line of products, visitsamrecover.com.

About ZetrOZ Systems

ZetrOZ Systems is an FDA cGMP and ISO 13585 medical technology company headquartered in the southern coastal region of Connecticut. The organization also has manufacturing facilities across the United States. ZetrOZ Systems produced UltrOZ, samSport and samPro 2.0 to provide safe and effective treatment options for prevalent conditions such as arthritis. Learn more atzetroz.comandsamrecover.com.

Media Contact

LedoraBrown

[emailprotected]

Related Images

real-world-outcomes-study-on-sam.jpg Real-world outcomes study on SAM wearable ultrasound treatment published in the Global Journal of Orthopedic Research 2020

SOURCE ZetrOZ Systems

See more here:
New Research Study Shows Efficacy of Sustained Acoustic Medicine as Add-on Therapy in Treating Sport-Related Injuries and Returning Athletes to Play -...

HELSINKI, Dec. 17, 2020 /PRNewswire/ -- Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc, an innovative drug development company, today announced that they have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis' CDNF and xCDNF therapies (Parkinson's disease) using Nanoform's proprietary biological nanoparticle technology.

The planned and non-exclusive collaboration is intended to assess the utility of Nanoform's latest platform technology for biologic drugs. The technology was recently launched, post filing of a provisional patent application with the US Patent Office, to enable production of biological nanoparticles as small as 50 nm.

Subject to finalizing definitive agreements, Nanoform will in this partnership carry out, for compensation on standard commercial terms, two Proof of Concept studies on Herantis' CDNF and xCDNF molecules leveraging Nanoform's novel platform and its in-house formulation expertise. The goal of the planned collaboration is to increase the probability of success for enhanced BBB (Blood-Brain-Barrier) penetration in the nasal drug delivery route for CDNF and x-CDNF.

Nanoform is committed to supporting Herantis in the development of these programs and has undertaken to invest, subject to certain customary conditions, 1,600,000 euros in a planned immediate directed share issue by Herantis.

"We are delighted to support Herantis Pharma in their development programs in CDNF and latest generation xCDNF molecules. Completing this deal validates the strong market interest in, and potential value that, Nanoform's platform technologies can add to pharmaceutical development programs and to the patient" said Prof. Edward Hggstrm, CEO of Nanoform.

"We look forward to working together to enhance and enable superior formulations of the pioneering new drugs we have developed. Nanoform's technologies show much promise for enhanced drug delivery applications in this complex and challenging field. It is our hope that this will open up new possibilities for improving the lives of patients with Parkinson's and other related diseases. We value the opportunity to enter into collaboration with Nanoform and look forward to what the future brings." said Dr. Craig Cook, CEO, Herantis Pharma.

For further information, please contact:

Prof. Edward Hggstrm, CEO

[emailprotected]/ +358 29 415 0684

For investor relations queries, please contact:

Henri von Haartman, Director of Investor Relations

[emailprotected]/ +46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The Company focuses on reducing attrition in clinical trials and on enhancing drug molecules' formulation performance through its nanoforming services. Nanoform's capabilities span the small to large molecule development space and the company focuses on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806.

For more information please visit http://www.nanoform.com

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company looking to break the boundaries of standard therapeutic approaches. Our regenerative medicine drug candidates include i. CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson's disease and other neurodegenerative diseases, and ii. Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. The Herantis programs are potentially disease modifying that treat the cause as well as symptoms of disease, and bring the innovation necessary to provide further treatment options in underserved diseases. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit https://www.herantis.com

Forward-Looking Statements (Nanoform)

This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform's strategy, business plans and focus. The words may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform's business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks specified in Nanoform's prospectus published (on May 22, 2020) in connection with Nanoform's initial public offering (the "Prospectus") under "Risk Factors" and in our other filings or documents furnished to the Finnish Financial Supervisory Authority in connection with the Prospectus. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nanoform/r/nanoform-and-herantis-partner-to-look-for-opportunities-to-enhance-bbb-penetration-of-cdnf-and-xcdnf,c3257538

The following files are available for download:

SOURCE Nanoform

Read the original post:
Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules - PRNewswire

Ashok Shetty is a professor in the Department of Molecular and Cellular Medicine and associate director for the Institute for Regenerative Medicine at the Texas A&M University College of Medicine.

Texas A&M Health Science Center

Thousands of American troops who were deployed in theFirst Gulf War were exposed to a variety of chemicals that resulted in psychological and physiological symptoms that health experts call Gulf War illness (GWI), previously called Gulf War syndrome.

Ashok Shetty, professor in the Department of Molecular and Cellular Medicineand associate director for the Institute for Regenerative Medicine at theTexas A&M University College of Medicine, has teamed up withKimberly Sullivan from the Boston University School of Public Health and Dr. Nancy Klimas Nova Southeastern University to investigate the extent and mechanisms of brain inflammation in veterans with GWI through a liquid biopsy approach. Their research efforts are being funded by a $1 million grant from the Department of Defense(DOD) over a three-year period.

The condition is characterized by a collection of unexplained chronic symptoms that can include gastrointestinal problems and dermatitis(a skin disorder) or central nervous system problems such ascognitive dysfunction, neuroinflammation, memory problems and depression.Nearly 30% of Gulf War veterans suffer from chronic GWI.Currently, the mechanisms underlying these persistent issues are unknown.

Shettysearlier studies on GWIfocused on theanimal model of GWI, recreating the conditions and chemicals veterans were exposed to during the war. He found that the animal models developed cognitive problems and had increased behavior that was associated with inflammation in the brain. His studies showed that the neuroinflammation in the brains of the animal models was progressive and had gotten worse over time, which explains why GWI is still prevalent in Gulf War veterans 30 years after the war.

Compared to an animal model approach, studying the brain in veterans with GWI is difficult. Therefore, most research with humans has been done through blood sampling, but its difficult to see if the results actually reflected what was happening in the brain. As a result, Shetty developed a liquid biopsy approach, which involves the characterization of the composition of brain-derived extracellular vesicles in the blood.

Shetty and his team will use this liquid biopsy approach to study neuroinflammation in the blood of Gulf War veterans beginning in early 2021.

The Sullivan and Klimas laboratories will collect blood samples of 50 veterans with GWI (patients) and 50 veterans without GWI (controls). Once the blood samples are collected, they will send the samples to Shettys laboratory. Shetty will then use the blood samples to isolate the extracellular vesicles (EV) membrane-enclosed nanosized vesicles that carry cargo such as proteins, lipids and micro-RNAs that come from the brain.

Once the extracellular vesicles are isolated, he will classify each one as a neuron-derived extracellular vesicle (NDEVs) or an astrocyte-derived extracellular vesicle (ADEVs) using a specific tagging technology. Then, Shetty will examine the cargo in the NDEVs and ADEVs, particularlyproinflammatory mediatorsand microRNAs using biochemical assays and RNA sequencing.

Because the composition of EVs reflects the physiological or pathological state of cells from which they are derived at the time of secretion, analysis of EVs derived from specific brain cells in the blood would help in the identification of biomarkers linked to chronic brain impairments, Shetty said.

What this approach means is by just looking at the vesicles, one can tell what is going on in the brain, even the brain cannot be directly studies. This technique of isolating extracellular vesicles was developed by Shetty in 2019, when he used an animal model approach.

Whatever is happening in the brain can be determined by characterizing brain-derived vesicles in the blood, Shetty said. It can be neuron-derived vesicles and astrocyte-derived vesicles, so this project is about that. But now, instead of animal models, we are studying actual veterans. From this human study, we can identify the extent of neuroinflammation in veterans.

Ultimately, this study will likely provide evidence as to why GWI is worse for some veterans compared to others, help diagnose the extent of brain inflammation in veterans with GWI and help determine whether GWI puts veterans at a higher risk for developing other neurological diseases.

The approach is also efficient in future clinical trials for monitoring the remission or progression of brain inflammation with apt treatment strategies, Shetty said.

Read more here:
Texas A&M Professor Awarded Department Of Defense Grant For Gulf War Illness Research - Texas A&M University Today

-Funding from the Bill & Melinda Gates Foundation will support research to enable CRISPR/Cas9-based therapies for HIV that can benefit patients worldwide-

ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics(Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the receipt of a grant from the Bill & Melinda Gates Foundation to research in vivo gene editing therapies for the treatment of HIV.

While we have demonstrated the promise of CRISPR/Cas9 gene editing ex vivo in sickle cell disease and beta thalassemia, an in vivo approach to editing hematopoietic stem cells could allow the transformative benefit of CRISPR/Cas9 to reach a broader array of patients, including those in low resource settings that lack sufficient infrastructure for stem cell transplantation, said Tony Ho, M.D., Executive Vice President and Head of Research & Development at CRISPR Therapeutics. We look forward to working on new therapies that could contribute to the global effort to reduce the burden of HIV.

The grant builds upon CRISPR Therapeutics proprietary CRISPR/Cas9 gene editing technology and expertise in editing hematopoietic stem cells and contributes to efforts to accelerate transformative medicines for global health.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR Forward-Looking StatementThis press release may contain a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements made by Dr. Ho in this press release, as well as regarding CRISPR Therapeutics expectations about any or all of the following: (i) the expected benefits of CRISPR Therapeutics research funded by the Bill & Melinda Gates Foundation and (ii) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words believes, anticipates, plans, expects and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: uncertainties inherent in the initiation and completion of preclinical studies for CRISPR Therapeutics product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be favorable and predictive of future results of the future trials; uncertainties about regulatory approvals to conduct trials or to market products; that future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics product candidates; potential impacts due to the coronavirus pandemic, such as the timing and progress of preclinical studies; uncertainties regarding the intellectual property protection for CRISPR Therapeutics technology and intellectual property belonging to third parties, and the outcome of proceedings (such as an interference, an opposition or a similar proceeding) involving all or any portion of such intellectual property; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics most recent annual report on Form 10-K, quarterly report on Form 10-Q, and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at http://www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

CRISPR THERAPEUTICS word mark and design logo are registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel EidesWCG on behalf of CRISPR+1-617-337-4167reides@wcgworld.com

See the original post here:
CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV - GlobeNewswire

DUBLIN--(BUSINESS WIRE)--The "Growth Opportunities in Digital, Microbiome-based, and Preventive Healthcare Technologies 2020" report has been added to ResearchAndMarkets.com's offering.

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across recent innovations in digital health, microbiome, and flu vaccines technologies. The TOE also provides insights across latest advancements for chronic pain management and COVID-19 testing.

The TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Key Topics Covered:

For more information about this report visit https://www.researchandmarkets.com/r/v6l8dq

See the article here:
Growth Opportunities in Digital, Microbiome-based, and Preventive Healthcare Technologies, 2020 Report - Focus on Latest Advancements for Chronic Pain...

New York, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts, 2020-2030" - https://www.reportlinker.com/p05995354/?utm_source=GNW However, over time, it has been demonstrated that such cultures are unable to accurately mimic the natural (in vivo) microenvironment. Moreover, cells cultured in monolayers are both morphologically and physiochemically different from their in vivo counterparts. This leads to differences in viability, growth rate, and function. Additionally, in adherent 2D culture systems, only 50% of the cell surface is exposed to the culture medium, which limits cell-to-cell and cell-to-medium interactions. In fact, a study reported that 95% of drugs that exhibited efficacy in 2D culture models failed in in vivo studies / human trials.

Advances in biotechnology and materials science have enabled the development of a variety of 3-dimensional (3D) cell culture models. These systems have been demonstrated to be capable of more accurately simulating the natural tissue microenvironment and, thereby, can help overcome most of the challenges associated with 2D systems. In addition, there are certain complex 3D cell culture models that are likely to soon replace animal models. In other words, 3D cell cultures are able to better simulate the natural tissue microenvironments, thereby, serving as better in vivo models for use in experimental research, including drug discovery / toxicity testing, development of regenerative medicine, tissue engineering, and stem cell research. This is anticipated to drive the adoption of such solutions in the foreseen future. Moreover, in a recent study, perfused 3D culture systems were used to emulate human bronchial tissue and airway cells, in order to study infectious respiratory diseases. Further, 3D cell cultures and organoid-based screening systems are being developed to facilitate the study of the pathogenesis of the novel coronavirus and support ongoing drug development efforts on this front. Based on the current trend of use, we are led to believe that the COVID-19 pandemic is likely to result in an increased demand for such solutions, presenting lucrative opportunities for companies engaged in this domain. In this context, the overall 3D cell culture market is anticipated to witness substantial growth in the coming years.

SCOPE OF THE REPORTThe 3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Organ-on-Chip, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (3rd Edition), 2020-2030 report features an extensive study of the current landscape and the likely future potential of 3D culture systems, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:An insightful assessment of the current market landscape of companies offering various 3D cell culture systems, along with information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information related to the companies providing 3D culture related services, and associated reagents / consumables.A detailed assessment of the overall landscape of scaffold based products, along with information on a number of relevant parameters, such as status of development (under development, developed not commercialized, and commercialized), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold based products, highlighting year of establishment, size of employee base, and geographical presence.A detailed assessment of the overall landscape of scaffold free products, along with information on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold free products, highlighting their year of establishment, size of employee base, and geographical presence.A detailed assessment of the overall landscape of 3D bioreactors, along with information on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. In addition, it presents details of the companies developing 3D bioreactors, highlighting year of establishment, size of employee base, and geographical presence.An insightful analysis, highlighting the applications (cancer research, drug discovery and toxicology, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.Elaborate profiles of prominent players (shortlisted based on number of products being offered) that are engaged in the development of 3D cell culture products. Each company profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments, and an informed future outlook.An analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products.An analysis of the various partnerships related to 3D cell culture products, which have been established between 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.An in-depth analysis of over 8,400 patents that have been filed / granted for 3D cell culture products, between 2015 and 2020, highlighting key trends associated with these patents, across type of patent, publication year, issuing authorities involved, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent characteristics and geography. It also includes a detailed patent valuation analysis.An in-depth discussion on the classification of 3D cell culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors.An elaborate discussion on the methods used for fabrication of 3D matrices and scaffolds, highlighting the materials used, the process of fabrication, merits and demerits, and the applications of different fabrication methods.Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in the development of 3D cell culture products.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the 3D cell culture market. Based on multiple parameters, such as business segment, price of 3D cell culture products, and likely adoption of the 3D cell culture products, we have provided informed estimates on the likely evolution of the 3D cell culture systems market in the mid to long term, for the time period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industrys growth.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players:Brigitte Angres (Co-founder, Cellendes)Bill Anderson (President and CEO, Synthecon)Anonymous (President and CEO, Anonymous)Anonymous (Co-founder and Vice President, Anonymous)Scott Brush (Vice President, BRTI Life Sciences)Malcolm Wilkinson (Managing Director, Kirkstall)Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel)Tanya Yankelevich (Director, Xylyx Bio)Jens Kelm (Chief Scientific Officer, InSphero)Walter Tinganelli (Group Leader, GSI)Darlene Thieken (Project Manager, Nanofiber Solutions)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGYThe data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information includeAnnual reportsInvestor presentationsSEC filingsIndustry databasesNews releases from company websitesGovernment policy documentsIndustry analysts views

While the focus has been on forecasting the market over the coming 10 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWEREDWho are the leading industry players engaged in the development of 3D cell culture products?What are the most popular 3D cell culture products?What are the different applications for which 3D cell culture products are currently being developed?What are the key factors that are likely to influence the evolution of this market?What is the trend of capital investments in the 3D cell culture systems market?Which partnership models are commonly adopted by stakeholders in this industry?How is the COVID-19 pandemic likely to impact the 3D cell culture systems market?How is the current and future opportunity likely to be distributed across key market segments?What are the anticipated future trends related to 3D cell culture systems market?

CHAPTER OUTLINESChapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of 3D cell culture systems market and its likely evolution in the short to mid-term and long term.Chapter 3 provides a general introduction to 3D culture systems, covering details related to the current and future trends in the domain. The chapter highlights the different types of cell cultures, the various methods of cell culturing and their application areas. The chapter also features a comparative analysis of 2D and 3D cultures, as well as highlights the current need and advantages of 3D culture systems.

Chapter 4 provides an overview of the classification of 3D culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. It also highlights, in detail, the underlying concepts, advantages and disadvantages of the aforementioned products.

Chapter 5 presents summaries of different techniques that are commonly used for fabrication of 3D matrices and scaffolds. It further provides information on the working principle, benefits and limitations associated with each method. In addition, the chapter features key takeaways from various research studies focused on matrices fabricated using the aforementioned methods.

Chapter 6 includes information on close to 160 industry players offering various 3D cell culture products. It features detailed analyses of these companies based on year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information the companies that offer 3D culture related services and associated reagents / consumables. It also highlights the contemporary market trends in four schematic representations, which include [A] a heat map representation illustrating the distribution of developers based on type of 3D cell culture format and company size, [B] an insightful tree map representation of the developers, distributed on the basis of type of product and company size, and [C] a world map representation highlighting the regional distribution of developer companies.

Chapter 7 includes information on close to 150 scaffold based products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed and not commercialized, and commercialized, type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold based products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 8 includes information on more than 60 scaffold free products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed not commercialized, and commercialized, type of product (attachment resistant surfaces, suspension systems, and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold free products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 9 includes information on more than 100 3D bioreactors that are either commercialized or under development. It features detailed analyses of these products based on the type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. The chapter also highlights the contributions of various companies developing 3D bioreactors, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 10 presents a detailed overview and analysis on the most popular application areas, which include cancer research, drug discovery and toxicity screening, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.

Chapter 11 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold based products (offering at least five hydrogel / ECM products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 12 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold free products (offering at least three organ-on-chip products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 13 features elaborate profiles of prominent players that are either engaged in the development or have developed 3D bioreactors (offering at least two bioreactors). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 14 features an analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products, highlighting the growing interest of the venture capital community and other strategic investors, in this domain.

Chapter 15 features in-depth analysis and discussion of the various partnerships inked between the players in this market, during the period, 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.

Chapter 16 provides an in-depth patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 8,400 patents that have been filed / granted for 3D cell culture products, since 2015, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authorities involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent valuation analysis.

Chapter 17 presents an insightful market forecast analysis, highlighting the likely growth of 3D cell culture systems market, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers.

Chapter 18 presents insights from the survey conducted for this study. We invited over 150 stakeholders involved in the development of 3D cell culture systems. The participants, who were primarily Founder / CXO / Senior Management level representatives of their respective companies, helped us develop a deeper understanding on the nature of their products / services and the associated commercial potential.

Chapter 19 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the 3D cell culture systems market.

Chapter 20 is a collection of transcripts of interviews conducted with various stakeholders in the industry. The chapter provides a brief overview of the companies and details of interviews held with Brigitte Angres (Co-founder, Cellendes), Bill Anderson (President and CEO, Synthecon), anonymous (President and CEO, Anonymous), anonymous (Co-founder and Vice President, Anonymous), Scott Brush (Vice President, BRTI Life Sciences), Malcolm Wilkinson (Managing Director, Kirkstall), Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel), Tanya Yankelevich (Director, Xylyx Bio), Jens Kelm (Chief Scientific Officer, InSphero), Walter Tinganelli (Group Leader, GSI), and Darlene Thieken (Project Manager, Nanofiber Solutions)Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix, which contains the list of companies and organizations mentioned in the report.Read the full report: https://www.reportlinker.com/p05995354/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more:
3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts,...

Pune, India, Dec. 14, 2020 (GLOBE NEWSWIRE) -- The report mentions that the Gene Therapy Market size was USD 3.61 billion in 2019 and is projected to reach USD 35.67 billion by 2027, exhibiting a CAGR of 33.6% during the forecast period. The global gene therapy market is set to gain momentum from the rising incidence of different types of cancer. The field of this therapy is undergoing several technological advancements that would help in treating cancer in those patients who are at high risks of getting affected by this disease through genetic mutations. In 2019, the U.S. generated USD 2.16 billion in terms of revenue. The country is expected to dominate throughout the coming years stoked by the increasing usage of advanced gene therapies for the treatment of rare conditions.

KEY INDUSTRY DEVELOPMENTS:

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/gene-therapy-market-100243

Increasing Innovations & Research Activities to Boost Growth

The U.S Food and Drug Administration (FDA) stated that it is expecting to receive more than 200 applications of this therapy by the end of 2020. This showcases that the rising number of research studies and innovations in this field would affect the gene therapy market growth positively in the near future. In North America, almost 208 companies are currently operating in this market. In addition to this, the Alliance for Regenerative Medicine declared that as of 2018, approximately 259 potential drug candidates are under Phase I clinical trials across the globe.

However, the outbreak of the COVID-19 pandemic is presently impacting the field of research. According to the director of the Office of Tissues and Advanced Therapy (FDA) named Wilson Brayan, nowadays the officials are prioritizing only those drugs that are associated with coronavirus.

To get to know more about the short-term & long-term impact of COVID-19 on this market, please click here: https://www.fortunebusinessinsights.com/industry-reports/gene-therapy-market-100243

The U.S. to Dominate Owing to Presence of Favorable Policies

In 2019, the U.S. generated USD 2.16 billion in terms of revenue. The country is expected to dominate throughout the coming years stoked by the increasing usage of advanced gene therapies for the treatment of rare conditions.

Besides, the presence of favorable reimbursement policies and guidelines would also help in propelling the market growth here. As this type of treatment is not legal in several developing nations, industry giants are emphasizing on the U.S. for launching their products.

Europe, on the other hand, is anticipated to grow significantly backed by the adoption of unique treatment options. Asia Pacific is set to hold a comparatively lower share on account of the decreasing usage of gene therapy because of its expensive nature.

Quick Buy - Gene Therapy Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100243

List of Key Players operating in Gene Therapy Market:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/gene-therapy-market-100243

Global Gene Therapy Market Segmentations:

By Application

Oncology

Neurology

Others

By Vector Type

Viral

Non-viral

By Distribution Channel

Hospitals

Clinics

Others

By Geography

U.S.

Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)

Asia-Pacific (Japan, China, and Rest of Asia- Pacific)

Rest of World

Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/gene-therapy-market-100243

SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

Have a Look at Related Reports:

India Peritoneal Dialysis Market Share & Industry Analysis, By Type (Continuous Ambulatory Peritoneal Dialysis (CAPD), Automated Peritoneal Dialysis (APD)), By Product (Devices (Cyclers/Machines), PD Solutions/Fluids, PD Sets, Catheters) Forecast, 2019-2025

Guidewire Market Share & Industry Analysis, By Product (Coronary Guidewire, Peripheral Guidewire, Urology Guidewire, Neurovascular Guidewire, and Others) By Material (Nitinol, Stainless Steel, and Others) By Coating (Coated and Non-Coated) By End User (Hospitals & Clinics, Diagnostic Centers, and Others) and Regional Forecast, 2019-2026

India Insulin Pumps Market Share & Industry Analysis, By Product (Insulin Pumps (Tethered Pumps and Patch Pumps) and Consumables (Reservoirs, Infusion Sets, and Others) and Region Forecast, 2019-2025

Lactose Market Share Trends & Industry Analysis, By Purity (Crude Lactose, Edible Lactose, and Refined-edible Grade Lactose), By Color (Yellow Lactose, Pale-yellow to White Lactose, and White Lactose), By Applications (Food, Feed, Infant Formula, and Pharmaceuticals), and Regional Forecast, 2019-2026

Contact Lenses Market Share & Industry Analysis, By Modality (Reusable and Disposable), By Design (Toric, Multi-focal, and Spherical), By Distribution Channel (Retail Stores, Online Stores, and Ophthalmlogists), and Regional Forecast, 2019-2026

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: sales@fortunebusinessinsights.comFortune Business InsightsLinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/global-gene-therapy-market-10136

Go here to see the original:
Gene Therapy Market Worth USD 35.67 Billion at 33.6% CAGR; Rising Prevalence of Spinal Muscular Atrophy to Augment Growth: Fortune Business Insights -...

I had REGENCare treatments in October, and I just again today, and theyre fantastic. They just help rejuvenate my entire system, help replenish the muscle tissue, help just heal any nagging injuries that are throughout my body. REGENCare treatments are fantastic and its an all-natural way to heal.

ATLANTA (PRWEB) December 14, 2020

Announcing the launch of REGENCare Life Magazine. Published in conjunction with Local Umbrellas C4 Lead Machine, the inaugural issue features interviews with Rob Gronkowski, the Atlanta Braves legendary Ryan Klesko and Atlantas Celebrity Anti-Aging Expert, Dr. Richard Ambrozic (@drrick), regarding the very latest in Regenerative Therapies designed to renew and restore function in the body. The magazines inaugural edition features stories and testimonials from professional athletes and many other patients benefiting from these Allograft Regenerative Therapies.

REGENCare Life Magazine features an interview with Tampa Bay Buccaneers tight end Rob Gronkowski by C. Christie Craig. (See Interview below.)

The highs and lows of football players are well known. When you are young, strong, and focused, the game has no limits. But the body can only take so many hits; there is a huge price to pay for years of playing hard on the field. Rob Gronk Gronkowski, one of the NFLs all-time greatest tight ends, knows this all too well. In 2019, Rob announced his retirement from the New England Patriots, needing a break to focus on his health and well-being. At 30 years old, he had an extraordinary run, making his mark in football history. Fans were devastated and Rob was hurting.

Today, after a multitude of various regenerative treatments throughout last year, Robs new nickname is Mr. Recovery. His body and mind are healed, and he has a fresh new deal with the Tampa Bay Buccaneers. The best part is hes going to share his most amazing discovery. In fact, he is ready to shout it out to all who will listen. Thats good news, because when it comes to overcoming pain, hes someone we should listen to carefully. Not only is he an amazing athlete; he is also a successful businessman and philanthropist.

Gronk was always well-loved by fans and teammates, and many thought his career was over. But he was not the type to give up, and he decided that pain was not going to mean the end of his story. How he eliminated it and got back on the field is an inspiring story for all of us. In this interview, Rob shares how he found his fire and returned to the NFL through regenerative care treatments. Here is the incredible story of his journey back to health and wellness in his own words.

Question: I am here with the greatest tight end in NFL history who now calls himself Mr. Recovery. After a litany of injuries, you are coming out of retirement this year and making your comeback with the Tampa Bay Buccaneers. How did this all happen?

Gronk: Thank you! I am super excited, super pumped up. I feel so good, you know. I let my body heal and recover. Ive been playing football for fifteen plus years, plus along with other sports, and with all this action Ive seen, my body just needed a little rest. I had to investigate and find connections to heal. Dr. Rick turned everything around for me. Its a full-time job as an athlete. Athletes dont just show up. We have to take care of our bodies and find solutions that work. The recovery is cake with Dr. Rick.

Question: Your journey back to health is unprecedented. Few NFL players return to action after retiring like you did. Allografts are the new buzz words for lasting recovery. Is this the type of therapy and injections you received from Dr. Rick at REGENCare?

Gronk: Yes, I had REGENCare treatments in October, and I just again today, and theyre fantastic. They just help rejuvenate my entire system, help replenish the muscle tissue, help just heal any nagging injuries that are throughout my body. REGENCare treatments are fantastic and its an all-natural way to heal. This treatment is exactly what I needed. I am sharing this information with others because this treatment isnt only for professional athletes like me. It can help everyone!

Question: How is your healing different with REGENCare Therapy compared to traditional treatment?

Gronk: In your early twenties you really dont get into the treatment. You just do the basics and the bare minimum. But as you get older, you have to treat your body more, you need to find new ways, and thats what Ive been doing over the last few years. Aside from the allografts, there are so many options at REGENCare. Im getting massages, doing vitamin IVs, and lying in the hyperbaric chamber. This chamber fills my body up with clean, pure oxygen. Without oxygen in your body, you are not going to survive! Its just spectacular when you can get more and more oxygen into your system. Your muscle tissues start feeling pliable and loose and it targets all those nagging injuries to help them heal. It is my favorite treatment because I get a nap and I am getting rejuvenated at the same time by all the oxygen. Its great. We also do a couple other treatments to help with recovery, stress management, improving sleep and diet.

Question: Do REGENCare Therapy treatments make a difference in how fast you recover and heal?

Gronk: I definitely feel a big difference. Back in the day, I would just let my body heal naturally, and when I say naturally, I would just do the bare minimum. I would be running around on it. I would be partying on the injury while it was trying to heal. But I was so young then, and I could get away with it. But now that I want to continue my career, and Im older, I learned that I needed to start adapting. You got to adapt to the change, you got to start adapting to your body. And you know, finding that adaptation includes a whole spectrum of healing treatments from allografts and finally, to proper nutrition.

Question: How does your focused mindset play a role in your healing? Is it an importantpart of your treatment process?

Gronk: Yeah, definitely! Some people can be telling you to do this, and you just got to stick with your gut. You got to stick with your heart, knowing what is best for your body. To know that, you have to go through a lot of experiences. Ive tried many, many things, and some do work for me. I focus on all the natural treatments that you could do for yourself. I find the best ones that suit me and enjoy em while doing em.

What would you tell your friends and teammates who are suffering from chronic pain and injuries about these regenerative treatments?

Gronk: Just get started on it now! The longer you wait, the harder it is going to be to heal that injury and nagging pain. The longer you wait, it gets more settled into your brain that you have that nagging pain. So hop on it ASAP, get moving, get cruising on it, find some good workouts, strengthen your core tight, and start small. Thats where it begins. You dont got to go big at all. Just start small and make little changes.

Question: So whats next for you? You have an exciting season with Tampa Bay, what are some of the things that youre doing to prepare?

Gronk: You know, Im just hanging out! Throwing footballs, doing football workouts, doing band workouts, doing some strength workouts, just doing it all at high speed. Its a lot of expectations for sure. Just have to go in and be a consistent player and youre just ready to go. Im just excited to get back out into the field and play some football and help out the team.

Question: If you were to leave a legacy behind, what would it be?

Gronk: Just working hard, being the best teammate that I can be and doing the best that I can to help out the team. Now that Dr. Rick has helped me to recover, I can achieve this and more.

Get your copy & learn more about how Allograft Regenerative Therapies can help you at https://www.REGENCare.life.

Regenerative Medicine Treatments at REGENCare

Our regenerative medicine treatments utilize regenerative medicine to encourage tissue healing throughout affected areas. REGENCare utilizes regenerative medicine allografts, Pulsed Electro-Magnetic Field technology to stimulate and exercise the cells and address cellular dysfunction and support overall wellness, Shockwave Therapy to promote regeneration and repair of the bones, tendons and other soft tissues, Georgias first PRISM Light Pod which uses specific wavelengths of light that pass through layers of skin and interact within the body to stimulate regrowth and repair, IV Hydration which provides the vitamins, minerals, and amino acids your body needs, Hyperbaric Oxygen Therapy which can significantly increase the concentration of circulating progenitor cells within the peripheral circulation system, and more. We may be able to help in orthopedic conditions, like osteoarthritis, meniscus and cartilage tears, tendinitis, joints and back pain, inflammation, hair restoration, skin rejuvenation and anti-aging treatments.

About Richard Ambrozic, MD, Founder and CEO, REGENCare:

Dr. Ambrozic (@drrick) earned his MD from the University of Alberta. He completed a residency in health prevention and family medicine at the University of British Columbia and has completed an anti-aging fellowship from the University of South Florida. The American College of Sports Medicine, American Academy of Anti-Aging Medicine, American Medical Association, Medical Association of Georgia, and the American Society for Laser Medicine and Surgery. He is a member of the Harvard Medical School Postgraduate Association. He is an expert in Allografts, Lasers, and Anti-Aging.

Dr. Ambrozic is the founder of REGENCare, with locations in Buckhead, Atlanta, Jupiter/Palm Beach Florida, and soon around the world. He treats professional athletes, celebrities, and patients from all walks of life interested in regenerative and anti-aging medicine. Healing the body naturally and safely, without pills and unnecessary surgery is most important. Dr. Ambrozic has traveled the world to bring the very latest and state-of-the-art regenerative medicine protocols, technology, and procedures to his clinics.

Please call our office to book your free consultation so Dr. Ambrozic and the REGENCare team can plot your course to better health.

Call 678-430-3039 or email at appointment@regencare.life.

Please visit our website at https://www.REGENCare.life

Please visit our Social Media:

https://www.instagram.com/drrick/https://www.facebook.com/richard.ambrozichttps://www.linkedin.com/in/dr-richard-ambrozic-70206124/

Contact:

REGENCareDr. Richard Ambrozic (@drrick)Office Phone: 678-430-3039 Email: appointment@regencare.lifeAddress: 240 Pharr Rd. Atlanta, GA 30305 (Buckhead Village)

Read the original post:
REGENCare Life Magazine Interviews NFL's 3X Super Bowl Champion, Rob Gronkowski, and Atlanta's Anti-Aging Expert, Dr. Richard Ambrozic, Regarding...

Arthritis is a disease with over 100 variations that affects350 million people around the globeincluding an alarming number of children. While these numbers may be discouraging, the cheering news is that natural remedies like borax, apple cider vinegar, turmeric, baking soda and blackstrap molasses are quite effective. Home treatments for arthritis can not only relieve pain but prompt the body to heal itself.

Natural remedies for arthritis address the pain, inflammation, stiffness, and limited range of motion. Supportive foods and supplements provide needed materials for the bodys own repair of joint degeneration.

There are many excellent natural remedies for arthritis and they can be tailored to individual needs. It may take a combination of remedies to bring full relief.

Borax is a compound that exists in deposits around the world. It is mined from the earth and used in a variety of commercial and home settings. Borax contains sodium, hydrogen, oxygen and boron. Boron is a mineral required by the body. Higher concentrations of boron are found in strong bones than in weak bones. Boron is needed by the body for proper calcium-magnesium balance, another factor in a healthy skeletal system. This video will provide more extensive information about using borax for arthritis.

Raw and organic apple cider vinegar provides trace nutrients to the body and helps the body to become more alkaline which reduces pain. 1-2 teaspoons of apple cider vinegar can be added to a glass of water. This tonic is consumed once or twice a day. Apple cider vinegar is a popular remedy for weight loss. Losing excess weight often reduces arthritis symptoms and risks.

When an imbalance in the bodys natural pH level is the primary causes of arthritis, baking soda is an effective treatment option. Baking soda helps neutralize the bodys acidic state and return the body to alkalinity. Baking soda also provides carbonates to the body. Baking soda is a popular natural remedy for gout, one form of very painful arthritis.

Blackstrap molasses is a densely packed food. It contains calcium, magnesium, iron potassium, zinc selenium, and B vitamins to name a few! Nutritional deficiencies are common causes of many diseases. Restoring necessary nutrients to the body can allow it to heal itself. 1 tablespoon of blackstrap molasses contains 200 mg of calcium, which is 20% of the RDA for calcium for adults 50 and under. Calcium is critical to bone health, and calcium from foods is more easily assimilated into the body. 1 tablespoon of blackstrap molasses contains 25% of the RDA of magnesium for adults. Magnesium is necessary for healthy bones and cartilage. Copper is needed by the body to form connective tissue. Blackstrap molasses is a source of copper. Take note of the nutritional content of individual brands of blackstrap molasses. The amounts of nutrients in molasses does vary from brand to brand.

Turmeric is an herbal anti-inflammatory and a wonderful natural pain remedy. It can be taken in capsule form or added to milk. Golden milk is a popular way to take turmeric and is quite palatable. Curcumin in turmeric is they key to turmeric'santi-inflammatory and pain reducing properties. Early studies about the use of curcumin for arthritis are encouraging.1

Turmeric has few side effects, especially when compared to over the counter ani-inflammatory medications.

A number of essential oils have anti-inflammatory properties. Frankincense and peppermint essential oils are each excellent topical treatments for arthritis pain.

Frankincense has a long history in herbal medicine as an anti-inflammatory. Peppermint essential oil has a cooling effect on the body. Using peppermint and frankincense together makes a pleasant smelling topical pain reliever.

While some people use either of these oils neat, (undiluted) it is generally recommended to use essential oils with a carrier oil. Coconut oil or castor oil are two great carrier oils for arthritis treatment as each one has its own healing properties.

Vitamin C is needed by the joints for the synthesis of collagen. Vitamin C is also a natural anti-inflammatory. Evidence suggests that vitamin C has analgesic properties for those with joint and other pain.2

Sodium ascorbate is the best form of vitamin C to take. It is easier on the stomach and less acidic than the ascorbic acid form.

Bone broth is gaining popularity as a remedy for many degenerative conditions, including arthritis. Perhaps it would be better to say that it is regaining popularity. Generations ago bone broth was a staple in homes and used on a regular basis. Bone broth is made by a low simmering of bones and cartilage for 12-48 hours. During this time the nutrients that make up the bones and joints are extracted. Bone broth is chock full of just the nutrients needed for bone and joint repair! It is not difficult to make bone broth at home. Alternately, gelatin, collagen or store bought bone broth can be used.

Extra pounds cause extra stress to the joints, which promotes pain and degeneration. For every pound that a body is overweight there is a four pound increase in pressure on the knee joints. Someone who carries around only a modest 15 pound excess is placing an extra 60 pounds of force on the knee joints. Additionally, excess fat cells can aggravate arthritis conditions due the the inflammatory chemicals that are produced in the fat cells.3

Losing weight can reduce pressure on joints and reduce the inflammatory response in the body. Losing weight is definitely worth the trouble to improve health on many fronts. Weight loss goes hand in hand with the next important arthritis remedy on this list.

Exercise helps strengthen the body, including the muscles and the bones. Stronger muscles mean there is less stress on and more support for the joints. Exercise also promotes effective circulation. Better circulation allows for the bodys repair mechanisms to take place at a faster rate. Swimming is a wonderful exercise for those with arthritis. Walking is pleasant and more easily available. If your doctor permits, small hand weights can be used to strengthen joints and muscles in the arms. (The legs will be getting the benefit of weight bearing exercise by virtue of carrying the body.)

Food is the primary vehicle for needed vitamins, minerals and other nutrients to enter the body. Making calories count with healthy and nutrient dense foods gives the body something to work with. Whether arthritis is caused by wear and tear, genetics, obesity, infection, autoimmune diseases, metabolic imbalances or nutritional deficiencies, quality nutrition will support healing or at least can help to slow down the progression of disease. Excessive amounts of sugar and processed foods fill up the body and keep it from getting needed nutrients. They also contribute to obesity, which aggravates arthritis. Supplements may still be necessary and helpful but they will never completely overcome damage done to a body that gets very little nutrition from food.

Some specific nutrients that arthritis suffers need and good sources of them are listed below:

Calcium - kale, milk, milk kefir, cheese, sardines, lentils, almonds

Magnesium - quinoa, black beans, brown rice, tofu, dark chocolate,avocados

Vitamin C - pineapple, strawberries, kiwi fruit, red peppers, papaya, broccoli

Vitamin D - fortified milk, cereal, salmon and tuna

Folate - chickpeas, lentils, broccoli, and spinach

In addition to quality foods, positive dietary changes include plenty of quality liquids. Even mild dehydration can contribute to pain. A well hydrated body feels better. Fluids keep toxins moving out of the body.

Keep coffee and sodas to a minimum. Both can cause the body to be more acidic, making pain worse and contributing to compromised health. Plenty of qualitywatershould be consumed daily. Avoid distilled water as it can leach important minerals from the body, especially the bones.

Herbal tea is a wonderful way to fulfill needs for fluid and nutrition.

Try this nettle infusion daily to boost the intake of nutrients to benefit overall health, including that of the bones.

Nettle Infusion

Bring water to a near boil. Place nettle leaf in a quart jar. Pour water into jar over the leaf. Allow the tea (an infusion is a strongly brewed tea) to steep without further heat for 12 hours. (Prepare before bed for use the next day.) Strain out the nettle leaf. Lightly sweeten with honey as desired. Consume 4 cups daily. This tea will keep for 24 hours in the refrigerator. Peppermint or spearmint leaf can be added for flavor.

Earth Clinic has had many success reports for many different manifestations of arthritis and joint pain including gout, rheumatoid arthritis, ankylosing spondylitis and degenerative disc disease.

Do you have a natural remedy for arthritis? Please send us some feedback!

Continue reading to learn how our readers have treated arthritis with natural remedies!

Arthritis, Art Solbrig RemedyBoraxOsteoarthritisTurmeric

Read more here:
Most Effective Natural Remedies for Arthritis